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Tau is a microtubule-associated protein that is typically found in the axons of neurons. The 
aggregation of the tau is a significant event in many neurodegenerative diseases including 
Alzheimer's disease. In these disease tau dissociates from microtubules and begins to form toxic 
insoluble intracellular tau aggregates.  The process of conversion of soluble monomeric tau to 
insoluble aggregates in not well understood. Differential conformational changes in pathological 
forms of the protein may affect its propensity for aggregation and function. Post translational 
modifications such as hyperphosphorylation or truncation may induce these conformational 
changes and alter aggregation and function. The studies described here used in vitro assays to 
determine how truncation affects tau conformation and how they can alter aggregation and 
function.  This information helps to describe how intrinsic differences due to modifications of 
tau can manifest themselves in the varying pathologies of tauopathies. Tau aggregation in a 
common mode of pathogenesis in tauopathies, including Alzheimer's disease. Tau aggregation 
correlates with dementia and neurodegeneration and is viewed as a potential therapeutic target 
for AD. Fungi have historically been a good source of medicinally important compounds. We 
identified secondary metabolites obtained from Aspergillus nidulans as tau aggregation 
inhibitors. We identified a novel class of tau aggregation inhibitors, azaphilones. Four of the 
azaphilones inhibited tau aggregation and disassembled pre-formed tau aggregates without 
inhibiting tau’s ability to polymerize microtubules. Preliminary NMR studies showed that our 
most potent azaphilone, aza-9 interacts with specific residues of tau protein in a dose dependent 
fashion. Aza-9 also disassembled tau aggregates formed by aggregation enhancing truncation 
mutant 1-391 in a dose dependent fashion. Azaphilones are therefore very promising lead 
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compounds for tau aggregation inhibitors, provide a novel scaffold for the same and represent a 
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Chapter I Introduction  
1.1 Tau Introduction 
Tau protein was identified from brain tissue by Weingarten et al. in 1975 as a microtubule 
associated protein (MAP) that promoted microtubule assembly1. Tau is one of the MAPs among 
the family of structural MAPs, including MAP1, MAP2, MAP4 and MAP6 which were first 
described as microtubule-stabilizing proteins2-4. Tau is a natively unfolded protein mainly found 
in neuronal axons where it binds to microtubules, is involved in their assembly and stabilization 
and in regulation of motor-driven axonal transport5, 6. In the year 1986, several reports came out 
showing that tau protein was a component of the neurofibrillary tangles (NFTs) or paired helical 
filaments (PHFs) found in brains of patients suffering from Alzheimer’s disease (AD)7-9. 
Phosphorylated tau protein was a major antigenic determinant of PHFs10. In the next few 
decades, tau was seen to play a major role in pathogenesis of a range of diseases, collectively 
called tauopathies11-13. It is now known that tau aggregation plays a major role in disease 
pathogenesis in AD and other tauopathies. Post translational modifications of tau protein such as 
phosphorylation14, truncation15, ubiquitination16, acetylation17, glycosylation18, and oxidation19 
may have a causative role in tau aggregation.  The effects of many of these modifications on 
aggregation are not well-characterized as yet.  
1.2 Tau structure  
The human tau gene is mainly expressed in the neurons of the central nervous system and the 
protein itself typically localizes to the axons of the neurons but can be found in the 
somatodendritic compartment as well.   Six isoforms of tau protein are expressed in the adult 
human brain. The six isoforms are the product of alternative splicing from a single gene [MAPT 
(microtubule-associated protein tau)] located on chromosome at position 17q21.3120, 21. The 
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isoforms differ from each other by the presence or absence of exon 10 at the C-terminal creating 
3-repeat and 4 –repeat isoforms of tau respectively (Figure 1). The 3R and 4R isoforms further 
differ by the absence of exons 2 and 3 at the N-terminal or presence of one or two of the same. 
The 3R and 4R isoforms are present in a 1:1 ratio in the cerebral cortex of healthy adults 22.   
Tau has very little secondary structure and has been described as a natively unfolded or 
intrinsically disordered protein23, 24. As seen in figure 1.1, the tau N-terminal domain contains 
exons E2 and E3. It is also called the projection domain of tau because upon binding to tubulin, 
the N terminal of tau projects away from the surface of the microtubule. The N-terminal domain 
of tau is followed by a proline-rich region. The proline rich region is relatively basic because of 
its high glycine and proline content. It is predicted that this region could play a role in spacing of 
microtubules allowing the cargo to travel through the axon by contracting and expanding the 
microtubule cytoskeleton to allow easier passage25. The C-terminal of tau protein contains the 
microtubule binding repeat (MTBR) region and therefore plays a major role in binding of tau to 
microtubules26. The presence of 3 or 4 MTBRs influences the binding affinity of tau isoforms to 
microtubules. These domains of tau play specific roles in the process of tau aggregation.  
1.3 Tau function  
Tau promotes formation of axonal microtubules, stabilizes them, and drives neurite outgrowth 27. 
A recent study showed that tau remains highly dynamic when bound to microtubules and small 
groups of tau residues bind tightly to microtubules, while the intervening parts stay flexible28. In 
neurons, microtubules act as tracks connecting the cell body and the tip of the axons, to transport 
cargo such as mitochondria29, lysosomes30, peroxisomes31 and many other endocytotic or 





Figure 1.1 Tau protein structure.  The human full length tau protein consists of 441 amino 
acids. The N-terminal region consists of exons 2 and 3 shown as N1 and N2 respectively in this 
diagram. The C-terminal region consists of four microtubule binding repeat (MTBR) domains.  
There is a proline-rich domain right before the MTBR region. The C-terminal domain along with 
the proline rich region is also called the microtubule binding domain. Exon 10 codes for the 
second repeat domain R2. In the human brain six tau isoforms are generated through alternative 
mRNA splicing of exons 2, 3, and 10 and range from 352 to 441 amino acids in length. The 3-







 Therefore, tau helps in maintaining axonal transport and cell shape32. Overexpression of tau 
preferentially slows down the plus-end directed intracellular transport mediated by kinesin motor 
proteins33, 34. The minus-end transport involving dynein is less affected by tau expression levels.  
Tau also has other functions such a membrane interactions or anchoring of enzymes. The N-
terminal projection domain has an important role in neuritic development and it mediates the 
interactions between the plasma membrane and microtubules35. Tau is also involved in signal 
transduction pathways which could affect the spatial distribution of MTs36, and also have 
structural interactions with phosphatases and MTs which might control the phosphorylation state 
of tau37.  Tau affects MT bundling and spacing which is known to be affected by the sizes of the 
tau isoforms38. Tau interacts with specific chaperone proteins which affect the functions of tau 
such that they may suppress the formation of NFTs39.  
1.4 Tau aggregation  
In the diseased state, tau is altered such that it loses its ability to bind to microtubules and is 
consequently released from microtubules. This leads to destabilization of microtubules and, in 
addition the unbound tau molecules form intracellular toxic tau aggregates. Therefore, 
conversion of soluble monomeric tau into insoluble tau aggregates, potentially results in both 
loss-of-function and gain-of-function toxicities 40. Tau molecules undergo a series of post-
translational modifications and conformational changes in neurons to attain a pro-aggregation tau 
conformation41. Tau aggregation plays a major role in pathogenesis of Alzheimer’s disease and 
other tauopathies. Tau aggregation correlates with the type and severity of cognitive impairment 
in Alzheimer’s disease42, and tau aggregation can lead to cell death and cognitive defects in 
cellular and animal models (reviewed in43).   
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Tau aggregates are found in different forms including paired helical filaments (PHFs), straight 
filaments (SF) and twisted ribbons. PHFs arise from aggregation of tau monomers and have a 
highly ordered β-sheet structure at their core. The tau molecules bind to each other via 
hexapeptide motif regions to form these β-sheet structures. The hexapeptide motifs can by 
themselves induce β-sheet formation leading to formation of tau aggregates and can act as seeds 
to induce full length tau molecules to aggregate44, 45. These motifs are found in the microtubule-
binding repeat region (MTBR) of tau protein. The hexapeptide motif regions are 275VQIINK280 
which is referred to as the PHF6* motif, and the 306VQIVYK311 which is referred to as the PHF6 
motif. The tau aggregation process takes place in two steps – nucleation and elongation. In the 
nucleation phase, tau monomers come together to form small oligomeric species of tau. Tau 
oligomers are known to be soluble and are more prevalent in human AD brain samples than was 
predicted before. Tau oligomers in human AD brain samples were 4-fold higher than those in the 
controls and the oligomers were seen to play a role in the frontal cortex tissue from AD brains46. 
The oligomers act as seeds that incorporate more tau monomers to form larger, fibrous 
aggregates. This is the elongation phase of tau aggregation. Tau aggregates have a core region 
which mainly contains regions of the protein around the hexapeptide motifs described above, and 
the core is surrounded by a ‘fuzzy coat’ which includes the N- and C-terminal regions of the 
protein47. Aggregates have different morphologies in different tauopathies, for example – NFTs 
in AD, Pick bodies in Pick’s disease and globose tangles in Progressive Supranuclear Palsy 
(PSP)48, 49. 
There are many unanswered questions about tau aggregation. We do not know the exact 
mechanism for the conversion of monomeric tau to aggregated tau. Several studies have been 
carried out trying to understand the roles post-translational modifications of tau including 
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phosphorylation and truncations, play in aggregation. Tau aggregates are variable in their length 
and morphology. They can be long filaments or small oligomers or a combination of both. We do 
not have conclusive evidence as to whether the long filaments, small oligomer aggregates, a 
combination of both or intermediate length filaments are the toxic species. Recently however 
finding supporting that the small oligomeric species are in fact the toxic species of tau have 
emerged50.  
1.5 Alzheimer’s disease and other tauopathies  
Tauopathies are a group of neurodegenerative diseases that are characterized by the presence of 
aggregates of tau, usually containing abnormally phosphorylated tau. The neurodegeneration is 
generally caused due to loss of tau’s ability to associate with microtubules51. Tauopathies can be 
differentiated based on the morphologies of the tau aggregates, the cell types affected, the 
location of tau aggregates in the brain and the related symptoms that correlate with the specific 
brain regions affected. The major tauopathies include Alzheimer’s disease, Frontotemporal 
Dementia with Parkinsonism Linked to Chromosome 17 (FTDP-17), Pick’s disease (PiD), 
progressive supranuclear palsy (PSP), Corticobasal degeneration (CBD) and argyrophilic grain 
disease (AGD).  
1.5.1 Alzheimer’s disease  
Alzheimer’s disease is the most common type of dementia that typically occurs in late adult life. 
It mainly causes problems with memory, thinking and behavior. The symptoms get worse with 
time, eventually reaching a point where they start interfering with everyday tasks, and ultimately 
can lead to death. The main pathogenic hallmarks of AD are presence of extracellular amyloid 
plaques primarily containing amyloid-β (Aβ) peptide and intracellular tau aggregates in the 
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brain52. The presence of tau aggregates is observed before the appearance of amyloid plaques 
and the amount of tau aggregation correlates well with disease progression and the loss of 
neuronal axons53. There is also a less likely possibility that tangles and plaques appear 
independent of each other. The tau aggregates are made up of all the six isoforms of tau and 
these isoforms are present in approximately the same proportions as are found in a normal 
brain54.  
The AD process begins in the axons and the tau lesions are mainly localized within the 
entorhinal region of the temporal lobe55. The tau aggregation then spreads to, and is restricted, to 
a few regions in medial portions of the temporal lobe. At this stage, some patients with mild 
cognitive impairment are diagnosed56. At the final stages of AD tau aggregation is seen in all 
cortical regions and severe lesions can be observed on Gallyas silver staining and AT8 
immunoreactivity studies57. Monoclonal antibody AT8 recognizes tau protein phosphorylated at 
both serine 202 and threonine 20558. At this stage usually initial provisional clinical AD 
diagnosis is made. Also, there is a theory of possible disease progression of pathogenic 
molecules of abnormal tau or oligomeric tau aggregates from the locus coeruleus to the 
transentorhinal region of the cerebral cortex via neuron-to-neuron transmission and transsynaptic 
transport59.  
The other main component of AD is Aβ- amyloid plaques. The amyloid hypothesis states that the 
soluble Aβ fragments are synaptotoxic and lead to formation of plaques and subsequently also 
play a role in development of intracellular NFTs. The gene coding for the amyloid precursor 
protein (APP) is located on chromosome 21. Triplication of this chromosome leads to increased 
prevalence of dementia in older people with Down syndrome60.  5% of AD cases are early-onset 
AD due to mutations in one of three genes: those encoding amyloid precursor protein (APP) and 
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presenilins 1 and 261.  Presenilins 1 and 2 are part of the protease complex that cleaves the APP 
to generate Aβ pathology in AD. The best known genetic risk factor of AD is the inheritance of 
the ε4 allele of the apolipoprotein E (APOE), which is associated with lipid metabolism.  
There have been many studies done to understand the relationship between tau aggregation and 
the amyloid cascade hypothesis – do these processes occur independently of each other, does tau 
aggregation precede amyloid plaque formation or is it the other way around? Studies using 
crosses of transgenic mice expressing mutant tau gene and mutant APP gene have shown that 
there is definite interaction between Aβ and tau that leads to increased NFT formation and 
distribution in regions of brain vulnerable to these lesions62. There are no tau mutations that are 
directly associated with AD unlike those in the APP gene. Therefore, many investigators and 
pharmaceutical companies believe that Aβ is a very promising target for disease therapy in 
Alzheimer’s disease. 
Meanwhile, there is strong evidence showing that tau plays a major role in AD disease 
pathogenesis. NFT accumulation more closely reflects antemortem clinical manifestations of the 
disease than plaque pathology42, 63. Specific mutations in the tau gene have been associated with 
a certain type of tauopathy now recognized as frontotemporal dementia with Parkinson linked 
chromosome 17 (FTDP-17)64, 65. Overexpression of wild-type tau or aggregation-enhancing 
mutant tau constructs in cellular or animal models has been shown to induce toxicity66.  In 
transgenic AD mouse models, the presence of tau is necessary along with Aβ to exert toxic 





1.5.2 Frontotemporal Dementia with Parkinsonism Linked to Chromosome 17 (FTDP-17) 
FTDP-17 is a group of disorders caused due to mutations in the tau gene. The patients suffer 
from cognitive, behavioral and motor disturbances. It is characterized by superficial cortical 
spongiform changes, frontotemporal atrophy with loss of neuronal cells and white and grey 
matter gliosis. Tau aggregates are seen in the brains of these patients69. There are 10 silent 
mutations and 31 missense mutations known in the tau gene that may lead to early-onset 
tauopathies. The FTDP-17 mutants have differential effects on tau aggregation and on tau’s 
ability to interact with microtubules. For example, P301L mutant aggregates at a much faster rate 
compared to wild type full length tau protein. 
1.5.3 Pick’s disease (PiD) 
PiD accounts for 0.4% to 2% of all the cases of dementia. The patients exhibit clinical 
abnormalities such as behavioral changes, language disruptions and problems with executive 
functions such as planning and organization. Neuroimaging shows focal cortical atrophy and 
hypoperfusion in the frontal and temporal lobes upon functional imaging, widespread 
degeneration of the white matter, chromatolytic neurons and the presence of Pick bodies (PB)70, 
71. Tau proteins are the main cytoskeletal components that are modified during the 
neurodegenerative changes72. They aggregate into straight and random filaments in PBs and the 
aggregates are made up almost exclusively of hyperphosphorylated 3R tau isoforms with the 
exception of serine 262. S262 is phosphorylated in AD but not in Pick bodies73, 74.  
1.5.4 Progressive supranuclear palsy (PSP) 
Patients suffering from PSP mainly show movement disorders along with personality changes, 
loss of balance, eye movement and difficulties in swallowing72. In PSP, globose neurofibrillary 
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tangles are found in the subcortical areas and occasionally in the central cortex and spinal cord. 
The neuritic changes are mainly displayed in the basal ganglia, subthalamus and brainstem 
regions but not in the frontal cortex like AD75. In the NFTs tau forms straight filaments and 
tubules that are different from the paired helical filaments found in AD75. In PSP, the levels of 
tau mRNA isoforms containing exon 10 are increased in the brainstem but not the frontal cortex 
or cerebellum. Therefore this may lead to an increase in four-repeat tau protein isoforms that 
may contribute to the formation of NFTs in PSP76. 
1.5.5 Corticobasal degeneration (CBD)  
CBD is a rare sporadic neurodegenerative disorder that is characterized by widespread neuronal 
and glial accumulation of tau aggregates mainly consisting of the 4R tau isoforms. The 
aggregates are composed of PHF and SF-like filaments that combine to form inclusions as well 
as neuropil threads. Neuropil threads are a group of fibrils that are identified by tau-specific 
antibodies and are associated with neurite projections77, 78. The clinical manifestations of CBD 
are diverse with progressive asymmetrical rigidity and apraxia, progressive aphasia, impaired 
ocular movements, and dementia79.  
1.5.6 Argyrophilic grain disease (AGD) 
AGD is a sporadic late-onset dementia that usually presents in combination with other sporadic 
tauopathies including AD pathology. It is a 4R tauopathy characterized by abundant neuropil 
grains (ArGs)80. The main constituent of ArGs is abnormally phosphorylated tau and they are 
mainly found in the entorhinal and transentorhinal cortices, the amygdala and the hypothalamic 
lateral tuberal nuclei. Additional neuropathological features include ballooned neurons and 
astrocytic tau pathology81.  
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1.6 Post translational modifications  
Tauopathies are characterized by the presence of aggregated tau deposits, but the causes or 
mechanisms of tau aggregation in sporadic tauopathies are not fully understood. Tau undergoes 
post translational modifications that could play a role in making tau more prone to aggregation or 
in reducing tau’s ability to bind to microtubules. Therefore, studying the effects of these post 
translational modifications may help in understanding the aggregation mechanisms. These 
modifications include phosphorylation, truncation, ubiquitination, acetylation, glycosylation and 
oxidation. 
1.6.1 Phosphorylation  
Full length tau has around 80 phosphorylation sites which means 20% of the molecule has the 
potential to be phosphorylated. Tau protein purified from AD brains has increased 
phosphorylation compared to that in normal healthy brains82. Tau is phosphorylated at 2 to 3 
sites in the healthy brain but can have around 5-9 moles of phosphate per mole of tau in protein 
purified from AD brains82. Abnormal tau phosphorylation reduces microtubule binding83, 84 and 
may enhance aggregation85, 86. Phosphorylation of tau in the brain is mainly regulated via kinases 
such as glycogen synthase kinase 3 (GSK3) and protein kinase A (PKA)10, 87 and phosphatases 
including are phosphoprotein phosphatase 2A (PP2A) and PP-1 88. Therefore changes in protein 
kinase and/or protein phosphatase activities could enhance tau phosphorylation causing loss-of 
function and/or gain-of function toxicities.  
1.6.2 Glycosylation 
The pathogenesis of tau in AD not only involves hyperphosphorylation but also glycosylation of 
tau in PHFs. Studies show a correlation between tau phosphorylation and glycosylation. The 
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glycosylation of tau is an early abnormality that could facilitate the subsequent abnormal 
hyperphosphorylation of tau in the AD brain89. Glycosylation of tau increases the stability of the 
PHF structure and also might induce oxidative stress, thereby contributing to pathogenesis in 
AD18.  
1.6.3 Acetylation   
Tau acetylation is another post translational modification which has not been well characterized. 
It was reported that the amount of tau acetylation is enhanced in patients at early stages of tau 
pathology and contributes to accumulation of phosphorylated tau90. Tau acetylation impairs tau-
microtubule interactions thereby inhibiting tau function and it promotes pathological tau 
aggregation. The lysine residue (K280) within the microtubule- binding motif has been identified 
as a major site of tau acetylation17. Therefore, modulation of tau acetylation could be a potential 
therapeutic strategy towards tauopathies.  
1.6.4 Ubiquitination and Oxidation  
Ubiquitination of tau is the first line of defense against tau accumulation. Therefore, 
ubiquitinated tau in NFTs could indicate that the cell was unable to degrade the protein due to 
the presence of protease- and proteasome resistant tau aggregates16, 91. Finally, oxidation of tau at 
Cysteine-322 affects tau conformation and aggregation as well19.  
1.6.5 Tau truncations 
Tau undergoes conformational changes when it transforms from its monomeric state to begin the 
aggregation/ polymerization process. The discovery of antibodies Alz-50 and MC-1 which 
identify specific conformations of tau supported this theory of conformational change. The 
folding of the tau molecule is accompanied by proteolytic truncation at both ends of the 
molecule92. The first evidence of truncated tau in AD brains was provided by mAb 423 that 
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recognized only tau proteins C-terminally truncated at Glu391 and decorated NFTs obtained 
from brains of AD patients93. Therefore it was established that truncated tau is a part of the 
pathological process of tau aggregation in AD94. In AD brains, tau truncations are known to 
occur at D13, E391 and D42195,96. The accumulation of truncated tau correlates with disease 
progression therefore may be contributing to the process of tau aggregation in AD brains97, 98.  
The amino and carboxyl termini play an important role in the process of tau aggregation. 
Portions of the N-terminus are necessary for the formation of the aggregated tau conformation 
and impact tau polymerization. Removal of the N-terminus leads to a decrease in the amount of 
tau aggregation99. The C-terminus of tau inhibits filament formation in vitro. Therefore, 
truncation of the C-terminal domain of tau aggravates tau aggregation100. The exact roles of the 
N- and C- termini have not been understood very well and further characterization is needed to 
understand their exact role in the aggregation mechanism.  
1.7 Inducing tau aggregation in vitro  
As mentioned previously, tau aggregation plays a major role in pathogenesis of tauopathies. It is 
therefore important to understand the molecular mechanisms that lead to abnormal aggregation 
of tau. It will help in development of better therapeutics targeting these underlying molecular 
mechanisms of pathogenesis. Monomeric tau has a very high energy barrier for aggregation. 
Even at very high concentrations, monomeric tau does not aggregate by itself. Therefore an 
inducer molecule is required to overcome this energy barrier and cause tau to aggregate. Inducer 
molecules such as heparin and arachidonic acid (ARA) are therefore used to drive rapid self-
association of tau molecules. 
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Inducer molecules fall into two major groups – polyanions including heparin101, 
polyglutamate102, RNA103 and fatty acid-like molecules including arachidonic acid (ARA)104, 
docosahexaenoic acid105 and alkyl sulfonate detergents106. The exact mechanism by which these 
molecules induce tau aggregation is not completely understood as yet, although one hypothesis is 
that clustering of the negative charges on the inducers could provide a template for the positively 
charged tau molecule to bind to and assemble25. The two most commonly used inducer 
molecules are ARA and heparin.  
 Heparin promotes polymerization of truncated tau containing mainly MTBR at a higher 
efficiency than polymerization of full length tau101. Further, elimination of a cysteine under 
oxidizing conditions enhances the polymerization by heparin. Heparin induced tau aggregation is 
enhanced by formation of tau dimers through cysteine cross-linking and inhibited via 
intramolecular cysteine cross-linking at position 291 and 322107. The filaments formed from 
heparin induction have morphological characteristics similar to PHFs 25. 
ARA induces tau aggregation of the full length tau protein at an efficient rate compared to 
heparin and also at physiological concentrations of tau107. The filament morphology is that of 
straight filaments but they have a high degree of structural similarity to PHFs supported by the 
fact that they are recognized by antibodies and fluorescent dyes that react with autopsy-derived 
PHFs and those induced by heparin. Finally, ARA induced filaments can nucleate from PHFs 
obtained from human AD brain108. 
1.8 Treatment for AD and other tauopathies  
The numbers of AD cases are increasing every year at a very fast rate and there are no effective 
treatments available currently which could actually stop or reverse the disease condition. AD is 
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the sixth leading cause of death in the US and it is the only cause of death in the top 10 in 
America that cannot be prevented or cured. Therefore, there is an urgent need for treatments for 
AD as well as other tauopathies. The treatment options currently available include altering the 
functioning of the neurotransmitters or neurotransmitter receptors. These drugs help in reducing 
the rate of progression of the disease, but none of them actually stop or reverse it.   
1.8.1 Currently available FDA approved drugs 
The U.S. Food and Drug Administration (FDA) has approved 5 drugs that can be used to treat 
symptoms of AD – donepezil, galantamine, rivastigmine, tacrine and memanatine109. Table 1.1 
summarizes the source, mechanism of action and the year the drug was approved for use by the 
FDA.  
Donepezil, galantamine, rivastigmine and tacrine are cholinesterase inhibitors (ChEIs).  In AD, 
the degeneration of cholinergic neurons in the basal forebrain leads to the loss of cholinergic 
neurotransmission in the cortex, hippocampus, and other regions of the brain therefore 
contributing to the impaired cognition observed in AD patients. Therefore, the concept of AD 
being a cholinergic deficiency condition was established which had an influence on early AD 
drug development eventually leading to identification, study and approval of cholinesterase 
inhibitors for the treatment of AD110. ChEIs primarily improve cholinergic neurotransmission by 
slowing down the degradation of acetylcholine (ACh) by the enzyme acetylcholinesterase 
(AChE), leading to increase in the levels of ACh which plays an important role in regulating 
memory, thinking, judgement and other thought processes110, 111.  
Memanatine is the first Alzheimer’s drug targeting the NMDA receptor.  It is also the only drug 
that has been shown to be effective in the later stages of AD. In 2005, the FDA declined to 
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approve using memanatine to treat mild Alzheimer’s disease cases. Memanatine works by 
uncompetitvely binding to and blocking NMDA receptors. Excessive influx of calcium ions 
through NMDA receptors due to glutamergic dysfunction results in neuronal death through 
mechanisms not completely understood112. Such excitotoxicity is seen in AD and memanatine is 
known to prevent this NMDA receptor mediated excitotoxicity without affecting normal synaptic 
activity113. Apart from these drugs, alternative therapies including use of nonsteroidal anti-
inflammatory drugs, vitamin E, selegiline, Ginkgo biloba extracts, estrogens, statins and 
behavioral and lifestyle changes have been explored as therapeutic options114.  
 The current treatments only delay the progression of symptoms associated with AD. Also, these 
drugs have severe side effects. Long-term use of ChEIs increases risk of bradycardia, which 
means the heart rate is slower than normal, and loss of consciousness (syncope) and their 
consequences115. Other common side effects include gastrointestinal anomalies including nausea 
and diarrhea. It also results in an overall reduction in synaptic functioning. Discontinuing these 
drugs may lead to loss of beneficial cognitive and functional effects that would not have been 
evident previously115.  
1.8.2 Therapeutic strategies aimed at targeting underlying molecular mechanisms in AD 
In an effort to find disease modifying treatments, the focus in the field of therapeutics in AD and 
other tauopathies has now shifted to targeting the underlying molecular mechanisms responsible 
for disease pathogenesis. These include the two main hallmarks of the disease – amyloid plaques 
and tau aggregates. Drugs targeting the components of the amyloid cascade hypothesis aim at 




Table 1.1 FDA approved drugs for treatment of AD.  
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1.8.2.1 Amyloid based therapeutics  
The amyloid targeting therapeutics could be sorted into several classes. The first is small 
molecules inhibiting β- or γ-secretases that generate Aβ from APP117 . Enhancing the activity of 
α- secretase to enhance the nonamyloidogenic pathway of APP processing is another approach to 
therapy towards AD118. The goal is to reduce the Aβ plaque load. The concern with these is that 
several γ-secretase inhibitors block the same step in Notch processing and could interfere with 
Notch signaling pathway proteins and other cell surface receptors. Signaling through Notch is 
involved in crucial cell-fate decisions during development and therefore targeting γ-secretases 
for the treatment of AD may risk toxicity caused by reduced Notch signaling119. The second 
attempts to prevent oligomerization of Aβ or enhance the plaque clearance from the cerebral 
cortex120, 121. This is mainly attempted by active Aβ clearance by promoting microglial 
activity122. The third is the use of anti-inflammatory drugs, which is based on the observation 
that progressive accumulation of Aβ causes an inflammatory response in the cerebral cortex123. 
The fourth approach is regulation of cholesterol homeostasis. Prolonged use of cholesterol-
lowering drugs is associated with lower incidence of AD124 and has been shown to reduce 
pathology in APP transgenic mice125.  Aβ aggregation is partially dependent on metal ions Cu2+ 
and Zn2+126.Therefore the fifth approach involves chelation of these ions, which could prevent 
Aβ deposition. APP mice treated with a known Cu2+/Zn2+ chelator showed a reduction in Aβ 
deposition127.  
AD drug development has been dominated by amyloid-based therapeutic approaches. Around 19 
drugs targeting amyloid have failed at randomized clinical trials or their development has been 
stalled128. Therefore alternative therapeutic strategies now need to be explored.  
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1.9 Tau based therapeutics  
Based on the results from all the clinical trials it is evident that targeting only the amyloid 
pathway is not effective in stopping or reversing disease pathology. In fact, clearance of Aβ 
using active immunization did not prevent tau pathology or neurodegeneration in human AD 
patients129. Therefore, it is important to develop alternative tau mediated therapies. The 
mechanisms of tau pathology are not clear but tau aggregation, phosphorylation and propagation 
are likely pathological mechanisms that lead to loss of function or gain of function of tau 
eventually causing neurodegeneration. There are a number of therapeutic strategies aimed at 
reducing tau- caused pathology such as inhibiting tau phosphorylation (Figure 1.2), enhancing 
MT stabilization, clearance of extracellular tau through tau immunotherapy, enhancing the 
protein degradation pathways, attenuation of inflammatory responses caused by tau pathology, 
inhibiting/regulation of other post translational modifications such as glycosylation, nitration and 
acetylation and finally inhibiting the tau aggregation process. A few of the currently popular 
therapeutic strategies are discussed in more detail below.  
1.9.1 Inhibiting tau phosphorylation  
Tau protein has around 80 potential phosphorylation sites and the phosphorylation state of the 
protein is regulated by the activities of tau protein kinases and phosphatases. Hyper 
phosphorylation of tau is an important step in neurodegeneration in tauopathies130. Therefore 
regulating activities of tau kinases and phosphatases are, potentially, good therapeutic 




1.9.1.1.  Inhibiting tau kinases  
There are many kinases for tau phosphorylation including glycogen synthase kinase 3 (GSK3), 
protein kinase A (PKA), mitogen activated protein kinases (MAPKs), cyclin dependent kinase 5 
(CDK5), cyclin dependent kinase1 (CDK1) and MT affinity regulating kinase 1 (MARK1). 
GSK-3 and CDK5 phosphorylate tau at many sites, have high expression levels in the brain and 
are associated with NFT pathology in AD131. Therefore, these are the most obvious targets for 
treatment.   
Lithium chloride which is a GSK-3 inhibitor prevented tau hyperphosphorylation and NFT 
formation in a mouse model but did not disassemble pre-formed tau aggregates132. Tideglusib is 
a novel GSK-3 inhibitor which reduced tau phosphorylation, Aβ amyloid deposits and prevented 
memory deficits in transgenic mice expressing APP and tau133. Recently, phase II trial of 
tideglusib for AD and PSP has been carried out. The results showed no clinical benefit over a 
short term but further dose- finding studies are yet to be done in the early disease stage134. Other 
than GSK-3 inhibitors, no other tau protein kinase inhibitors have entered clinical trials. This 
could be because these kinases have multiple substrates and therefore are more prone to causing 








Figure 1.2  
 
Figure 1.2 Tau-based therapeutics. In an adult human brain, tau is bound to microtubules 
through MTBR regions (4 repeat). When in diseased state, tau is altered such that it loses its 
ability to bind to MTs. The altered unbound tau monomers sequester functional tau monomers to 
form oligomers and eventually toxic tau aggregates. Due to loss of tau binding, microtubule 
structure is also destabilized. One of the most frequent and studied reasons for loss of 
microtubule binding is hyperphosphorylation. A number of other posttranslational modifications 
such as ubiquination, glycosylation, phosphorylation, acetylation, oxidation or truncation due to 
caspases may potentiate the dynamics of oligomerization or aggregate formation. There are 
different types of pathological tau lesions that differ in appearance or content such as NFTs, Pick 
bodies, which contain only 3-repeat isoforms, or other forms. Potential therapeutic strategies are 








1.9.1.2 Activation of phosphatases 
The two important phosphatases that are affected in AD are phosphoprotein phosphatase 2A 
(PP2A) and PP-1136-138. PP2A accounts for more than 70% of all phosphoseryl/phosphothreonyl 
activity in the human brain139. In the adult human brain, PP2A regulates the phosphorylation of 
tau that suppresses MT assembly activity and this suggests that PP2A might be a good target for 
therapeutics140. PP2A is a part of multiple signal transduction pathways regulating normal 
cellular homeostasis, however, and targeting it for therapeutics might cause many unwanted side 
effects. Sodium selenite has shown to stabilize PP2A-tau complexes. In transgenic AD mice 
models treated with sodium selenite, there was reduced tau pathology making it a promising lead 
compound for therapeutics141. Memanatine has also shown the ability to enhance PP2A activity 
indirectly, therefore attenuating tau hyperphosphorylation in vitro142. Further, it was seen that 
treatment with memantine for one year results in significant decrease in the levels of 
phosphorylated tau in CSF of AD patients143.  
Tau protein function is regulated by a balance in activities of phosphatases and kinases and 
therefore targeting the same raises the concern of affecting the normal tau regulation. 
1.9.2 MT stabilization  
The main function of tau is to promote MT assembly. Post translational modifications like 
hyperphosphorylation alter tau such that it no longer binds to microtubules, leading to MT 
destabilization and aggregation of unbound altered tau molecules144. This impairs MT stability, 
axonal transport and accumulation of tau aggregates. MT stabilizing drugs could therefore rescue 
these functional impairments. Paclitaxel is a MT stabilizing drug used for cancer treatment. 
When an AD mouse model was treated with paclitaxel, there was improvement in fast axonal 
23 
 
transport, MT density and overall increase in motor function145. Paclitaxel has poor blood-brain 
barrier permeability however, and therefore is not suitable for treatment. Davunetide is another 
MT stabilizing drug which reached phase II clinical trials for treatment of tauopathies. The main 
mechanism of action of davunetide is to stabilize MTs, but the drug does not appear to be 
directly involved in polymerization or dynamics of reconstituted neural MTs 146. Epothilone is 
another MT stabilizing drug which showed reduction in tau pathology in the forebrain and an 
increase in the hippocampal neuronal integrity in a PS19 tauopathy mouse models147. In another 
study in a different tau transgenic mouse model, rTg4510, there was an improvement in 
cognitive function and reduction in tau pathology upon treatment with very low doses of a drug 
similar to epithilone, BMS-241027148. Therefore, MT stabilizing drugs are potentially good 
therapeutic drugs for treatment of tauopathies. Clinical trials of these drugs are currently going 
on. Microtubules are involved in many regular cell processes such as cell division, and use of 
MT stabilizing drugs can impair the dynamic nature of the MTs therefore leading to cell death. 
1.9.3 Enhancement of tau clearance mechanisms 
The Hsp70/CHIP chaperone system plays an important role in selective degradation of altered 
tau species including phosphorylated tau, and in regulation of tau turnover149. Dysregulation of 
such ubiquitin-proteosomal pathways could be responsible for tau aggregation. Therefore, 
enhancing degradation of pathological tau, including tau oligomers or fibrils, is yet another 
strategy for tau based therapeutics. Hsp90 plays an important role in maintaining the 
degenerative phenotype of tau in the diseased state. Hsp90 could be binding to tau inducing a 
conformational change making it more accessible for phosphorylation by GSK3 and its 
aggregation. In a tauopathy mouse model, JNPL3, use of an Hsp90 inhibitor resulted in reduction 
of hyperphosphorylated tau and tau aggregates in the brain150.  On the other hand, inhibiting 
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Hsp90 also leads to upregulation of heat shock transcription actor, which causes increases 
expression of multiple different heat shock proteins (Hsps), which leads to unintended side 
effects that could negate the effects of inhibition of Hsp90. Therefore, cochaperones of Hsp90 
are also now being targeted to yield more specific effects. For example, Withaferin A is a 
compound that inhibits cochaperone of Hsp90, Cdc37. Withaferin A was shown to decrease tau 
aggregates in mice and also leads to increase of Hsp70 and Hsp27 levels (reviewed in151).  
The autophagy-lysosomal system also plays an important role in degradation of tau aggregates, 
especially the larger aggregates which use three different pathways152. Trehalose is an activator 
of autophagy. When Trehalose was administered to transgenic mice expressing a P301S human 
tau mutant, it reduced tau phosphorylation in neurons and also the amount of insoluble tau 
protein and also improved neuronal survival153. This pathway potentially makes a very good 
therapeutic target because it specifically targets abnormal tau. A study showed that a caspase 
cleaved form of tau, which is more toxic than full length tau, is preferentially degraded via 
autophagy with a faster turnover than wild type tau154.  This strategy of tau based therapeutics 
would not affect the physiological functions of tau and therefore could be of tremendous 
therapeutic value.  
1.9.4 Inhibition of tau pathology propagation 
It is now known that tau pathology can spread from one cell to another via extracellular tau 
aggregates155. The hypothesis is that these aggregates can enter the cell cytoplasm and interact 
with normal endogenous tau and induce tau fibrillization by acting as a template for nucleation 
or seeding156. If this hypothesis is correct, removal or degradation of extracellular tau aggregates 
is a promising therapeutic strategy to stop disease progression. Immunotherapy to remove 
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extracellular tau aggregates looks promising based on a number of studies conducted in 
transgenic tau mouse models using passive immunization or active immunization157-159. 
1.9.5 Tau aggregation inhibitors 
Tau aggregation is caused when natively unfolded sequences in the MTBR region of tau 
monomers undergo a conformational change due to post translational modifications like 
phosphorylation, to form β-sheet structures and to form NFTs. It is believed that small molecules 
could interact with the β-sheet structures to inhibit tau aggregation. Recently, a tau aggregation 
inhibitor, a stable, reduced form of methylthioninium chloride has reached three phase-3 clinical 
trials, one for the treatment of Pick’s disease and two studies for AD160. Tau aggregation 
inhibitors (TAIs) identified to date belong to many different chemical classes as will be 
discussed below.  
1.9.5.1 Polyphenols  
Polyphenols are often biosynthesized by plants and are known for their potential antibiotic, 
antidiabetic and neuroprotective properties161. These are characterized by the presence of one or 
more hydroxyl groups (-OH) bound to an aromatic benzene ring. Many polyphenols have been 
identified in high throughput screens (HTS) for amyloid-aggregation inhibition and these inhibit 
a variety of amyloidogenic aggregates like those of α-synuclein, Aβ40 and tau among others162-
164.  Oleuropein aglycone is a natural phenolic derivative which inhibits tau aggregation at low 
micromolar concentrations165. This compound was found to be more active than methylene blue 
on both wild-type tau and aggregation enhancing mutant tau protein P301L165.  Myricetin is 
another polyphenol with an IC50 of 1.2µM and which may be interfering with the elongation 
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phase in fibril assembly162. (-)-Epi-gallocatechine (EGCG) is a polyphenol which has an IC50 
value of 1.8 µM for tau aggregates162.  
1.9.5.2. Anthraquinones  
Anthraquinones are close analogues of polyphenols. Several anthraquinones sharing a tricyclic 
aromatic ring system with some modifications have shown tau aggregation inhibition abilities 
and are known for their intercalating capabilities. Emodin, Daunorubicin, Adriamycin, PHF016 
and PHF005 are anthraquinones which have shown the ability to inhibit tau filament assembly 
and also induce aggregation of preformed aggregates of tau166. Several anthraquinones are Aβ 
aggregation inhibitors and molecular modelling suggests that these compounds have the common 
ability to adopt a specific three-dimensional pharmacophore conformation with aromatic rings 
bound to hydrophobic regions and prevent it from forming fibrils167.  
1.9.5.3 Rhodanine- based inhibitors  
Rhodanines were identified as tau aggregation inhibitors (TAIs) in a screen, and the scaffold was 
further explored via the synthesis of a focused library168. These compounds could inhibit tau 
aggregation and also promote filament disassembly at 100-600 nM concentration. They showed 
activity in cellular assays without cytotoxicity and didn’t interfere with tau’s ability to promote 
MT assembly168.  bb14, an inhibitor from the rhodanine class showed a reversal of toxicity 
caused by tau aggregation when used in cell culture models (N2a cells expressing mutant tau), in 
a C.elegans model expressing proaggregant tau species169 and in an organotypic slice model 




1.9.5.4 Phenylthiazolylhydrazide (PTH) inhibitors  
PTHs were obtained as hits against tau aggregation in an initial ligand-based virtual screen of 
200 000 compounds171. BSc3094, an inhibitor belonging to the PTH class, inhibited tau 
aggregation with an IC50 of 1.6 µM and for filament disassembly a DC50 of 0.7 µM for a 10 µM 
K19. Further, NMR studies indicate that BSc3094 binds to monomeric tau, therefore maybe 
shifting tau conformation to form off-pathway tau species172. These compounds are potential 
producers of radical oxidative species (ROS). The formation of reactive acyl radicals has been 
reported in other studies using these compounds and therefore would require further testing173.  
1.9.5.5 N- Phenylamine inhibitors  
N-phenylamine derivatives were identified as TAIs in a screen. These compounds inhibited tau 
aggregation in cell models of tauopathy as well174. The effects were investigated on an inducible 
N2a cell model of tauopathy. Upon incubation with 10 µM of B4A1, a phenylamine inhibitor, 
for a minimum of 5 days, the Thioflavin S (ThS) signal in cells decreased by 70% compared to 
untreated control and the cell viability returned to normal as well.  
1.9.5.6 Benzothiazoles  
Benzothiazoles are heteroaromatic structures with a 1, 3-thiazole ring and are known to display 
high affinities for β-sheet structures175. Cyanine dyes which are characterized by a polymethine 
chain linking two benzothiazoles have been identified as TAIs. N744 is an inhibitor belonging to 
this group of compounds which inhibits tau aggregation in vitro with an IC50 of 380 nM and 




1.9.5.7 Aminothienopyridazines (APTZs) 
APTZs were identified in a quantitative HTS of approximately 292000 compounds to inhibit tau 
assembly. ATPZs inhibited tau aggregation at IC50 values in the range of 5-7 µM and did not 
interfere with tau-mediated MT assembly177.  APTZs act by a mechanism that differs depending 
on the tau isoforms. Active APTZs were found to promote oxidation of the two cysteine residues 
in 4R tau isoforms by a redox recycling mechanism. This results in formation of disulfide-
containing compact monomeric tau molecules which were resistant to aggregation. But, in 3R 
tau isoforms, APTZs facilitated intermolecular disulfide formation leading to dimers which act 
as seeds for tau aggregation178. This could affect their viability as a therapeutic agent.  
1.10 Thesis overview  
Tauopathies are one of the greatest health concerns currently and there are no prevention 
strategies or effective treatments in sight. It is therefore crucial that researchers find a safe and 
successful therapeutic treatment soon. As shown in figure 1.2, there are several strategies being 
tested to stop or reverse the disease progression. The studies are in preliminary stages of 
development and a small number of compounds have reached the final stages of clinical trials. At 
this stage I cannot comment upon whether one treatment strategy is better than the other. 
Tauopathies are a very complex group of neurodegenerative diseases and we do not have enough 
knowledge about what initiates tau aggregation, why the pathologies are so varied, or what is the 
mechanism linking tau aggregation to its toxicity. There is a need to conduct research on both the 
fronts – 1) Understanding tau aggregation and 2) finding an effective treatment for the same.  
The first part of the study described here was designed to characterize how the aggregation and 
functions of tau are affected by the site of truncation. Characterizing these differences will assist 
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in elucidating the mechanisms of initiation of tau aggregation as well as how it may be exerting 
its toxic effects. We characterized the tau aggregation and function in vitro. Truncation of tau is 
known to occur in tauopathies. Truncated tau is seen in NFTs obtained from human AD patients. 
Truncation clearly plays a role in disease pathogenesis by affecting tau’s function and 
aggregation. Eight truncation mutants were generated in the full length tau isoform. I determined 
the differences within the truncation mutants through several assays designed to measure and 
characterize the aggregation of the protein, as well as its ability to stabilize microtubule 
polymerization.  
In the second part of the study, secondary metabolites obtained from Aspergillus nidulans 
containing aromatic ring structures were screened for their ability to inhibit tau aggregation. We 
chose seventeen compounds based on their structural similarity to previously identified tau 
aggregation inhibitors (TAIs). The effect of the compounds was measured through assays 
designed to measure the tau aggregation and examine filament morphology after treatment with 
the compounds. We identified three compounds which inhibited tau aggregation. One of the 
compounds was an intermediate in the azaphilone biosynthesis pathway. Dr. Berl Oakley and his 
colleagues generated a small library of azaphilones obtained from asperbenzaldehyde. We sought 
to determine whether these eleven azaphilones retained any tau aggregation inhibition activity 
observed in asperbenzaldehyde. We carried out several in vitro assays designed to test the 
activity of the compounds on tau filament assembly process and pre-formed tau aggregates. We 
characterized the aggregates formed after compound treatment to assess their toxicity. We 
determined the effect of the compounds on tau’s ability to stabilize microtubule polymerization.  
Finally I began a project where I started characterizing the interaction between the compounds 
and tau protein using NMR. I obtained preliminary results regarding the possible residues 
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involved in the interaction. Further, I tested the most potent compound for its activity against an 
aggregation enhancing tau truncation mutant. This was to test whether the compound would be 












Chapter II Effects of tau truncations on Aggregation and Microtubule Interactions 
2.1 Introduction  
Aggregation of the microtubule-associated protein tau is a significant event in the progress of 
certain neurodegenerative diseases termed tauopathies. A large portion of the current research in 
the field is focused on trying to understand the mechanisms and factors affecting tau filament 
formation, which should eventually help in finding better therapeutic strategies for tauopathies. 
Tau undergoes many post translational modifications which alter the conformation of tau protein 
such that it is more prone to aggregation. Tau phosphorylation has been studied extensively and 
is known to play a major role in tau pathogenesis179. Truncation of tau is another post 
translational modification that is known to cause conformational changes that induce a 
misfolding cascade in Alzheimer’s disease (AD) and other tauopathies180. Truncated tau is seen 
in the NFTs obtained from human AD patients. In fact, protein truncations are known to play a 
major role in pathogenesis of many other human degenerative disorders such as α-synuclein in 
Parkinson’s Disease PD181, TDP-43(TAR DNA-binding protein 43) in FTLD (Frontotemporal 
Lobar Dementia) 182 and huntingtin in HD(Huntington’s Disease)182.  
Tau is a substrate for many caspases. Caspase-6 and caspase-3 cleaved tau fragments are 
associated with early as well as late development of NFTs and correlate well with cognitive 
decline97, 98, 183. Truncated tau can be identified using specific antibodies such as MN423 and 
TauC395.  MN423, generated in mice immunized with morphologically intact pronase-resistant 
PHF core, recognizes the compact fold of the PHF core tau truncated at Glu39193. TauC3 
recognizes tau truncated at Asp 421, which has a different conformation from that of normal tau. 
DC11 is a truncation-dependent conformational antibody that recognizes altered tau in AD 
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brains184. DC11 recognizes neither native healthy tau nor its full length recombinant counterpart. 
However, this monoclonal antibody showed strong immunoreactivity with truncated tau 
(residues 151-421). This antibody revealed that a range of truncated tau species including N- and 
C-terminal truncations possess pathological conformations of tau. A specific sequence of events 
for truncations has been suggested92. Alz50 conformation is first formed and is seen in pre-tangle 
neurons185. Alz50 has a discontinuous epitope consisting of a.a. 2-10 from the amino terminal of 
tau and a.a 312-342 from the MTBR, and therefore is conformation dependent (Figure 2.1). After 
NFT formation, truncation occurs at both the amino- and carboxyl-termini. Alz50 positive tau 
aggregates are reactive to Tau-C3 which means they are truncated at D421186.  They are also 
reactive to Tau-66 antibody, which is also a conformational antibody dependent on the proline-
rich region of tau interacting with MTBR. Once tau is in the tau-66 conformation, it is cleaved 
more extensively in NFTs and becomes positive for MN423 that detects the truncation at E391. 
It has been shown in in vivo studies that activation of executioner caspases in neurons in 
transgenic mice, led to cleavage at D421, followed by formation of thioflavin-S positive NFTs 
and tangle-related conformational epitopes187. Thioflavin S is a dye which binds to amyloid 
strucutres and can be used to identify tau aggregates. When truncated tau proteins were 
expressed in brains of transgenic animal models, neurodegeneration was observed. Truncated tau 
induced hyperphosphorylation and formation of tau aggregates that were characteristic of AD188. 
The expression of truncated-tau activated inflammatory responses such as activation of microglia 
and leukocyte infiltration189. It further induced oxidative stress as well190. Further, when human a 
truncated tau transgene was expressed in a rat model, it resulted in sequestration of endogenous 
rat tau proteins and in their fragmentation and aggregation. It is therefore believed that few forms 
of truncated tau may have the potential to initiate and drive the tau truncation cascade191.  
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Figure 2.1  
 
Figure 2.1 Conformations of monomeric tau. In the figures, the red squares are the 
microtubule binding repeats (MTBR) of tau. The blue squares are the exons in the N terminal. In 
a normal condition tau attains a global folding conformation, where the C-terminal folds over the 
MTBR. In a diseased state two conformations of tau have been identified. The Alz50 and the 
Tau66 conformations are shown in the figure above. They form a more compact structure 
making tau prone to aggregation. Antibodies recognizing these conformations do not show 








It is important to study the isolated effects of tau truncations on aggregation mechanisms and tau 
function. The N-terminal and C-terminal regions of tau protein are involved in maintaining the 
global hairpin conformation of tau as well as the Alz 50 and tau 66 conformations that are found 
in the diseased condition. Removal of a.a. 2-18 from the amino-terminal portion of tau that 
overlaps with the Alz 50 epitope, inhibits tau polymerization in vitro99. Interaction of the N-
terminal region with the MTBR region of tau may be required for aggregation. Removal of 
amino acids from the C terminus of tau greatly increases the rate and extent of tau 
polymerization100. Therefore the C-terminus plays an inhibitory role in tau aggregation. There 
are unanswered questions regarding which stretches of amino acids in the N- and C-termini of 
tau play a crucial role in tau aggregation and MT stabilization. N-terminal and C-terminal 
truncation mutants will affect tau conformations and therefore affect aggregation and MT 
stabilization. Understanding the effects of tau truncations on tau conformation and MT 
stabilization will help in understanding their roles in aggregation mechanisms.  
We constructed eight truncation mutants in the background of full-length tau in vitro, which 
included five N-terminal truncations, two C-terminal truncations and one mutant with both N and 
C terminal truncations (Figure 2.2). The truncation mutants used in the study are shown in Table 
2.1. We chose these mutants because prior studies have shown that some of these truncations or 
similar truncations can influence tau aggregation (Table 2.1). We found that the truncations had 
different effects on the aggregation and MT interactions of tau. The differences in aggregation 
amounts, kinetics and filament morphologies helped in our understanding of pathology resulting 









Figure 2.2 Truncations used in this study. All truncations constructs were derived from full 
length tau construct (labelled). The N and C terminals of each construct are labelled in the 
diagram. The two N-terminal exons, e2 and e3, have been labelled as N1 and N2 respectively. 
The four MTBR regions are R1-R4.  The respective truncations have been labelled with their 
specific names. The five amino terminal truncations are 14-441, 43-441, 81-441, 201-441 and 
256-441. The two carboxyl terminal truncations included are 1-391 and 1-421. One mutant 






Table 2.1: Tau truncations used in this study  
 
C-Truncation Mutants 
1-421  C-terminal Caspase 3 cleavage site, elevated in Alzheimer’s disease97  
1-391 MN423 antibody site, elevated in Alzheimer’s disease47  
N-Truncation Mutants 
14-441 N-terminal Caspase 6 cleavage site96 
43-441 Removes N-terminal region that binds inhibitory N-terminal peptides192 
81-441 Removes N-terminal hydrophobic region (amino acids 75-80) (predicted) 
201-441 Removes the majority of the N-terminal region of tau, but leaves a 
hydrophobic region involved in tau binding to microtubules (predicted) 
256-441 Complete removal of N-terminal region and proline-rich region of tau 
(predicted) 
N- and C –truncation mutant  
256-391 Approximates the PHF core193 
 




2.2 Experimental Procedures 
2.2.1 Protein expression and purification.  All wild-type (WT) and truncation constructs were 
expressed and purified as described previously194.  The mutagenesis was done using the 
Quikchange site-directed mutagenesis kit from Stratagene (La Jolla, CA). The following 
truncations were generated in a full-length 2N4R tau background contained in a pT7C vector: 
14-441, 43-441, 81-441, 201-441, 256-441, 1-391, 1-421 and 256-391. 
2.2.2 Arachidonic acid-induced polymerization.  Recombinant WT and truncated tau proteins, 
at a concentration of 2 μM, were incubated in buffer containing 0.1 mM EDTA, 5 mM 
dithiothreitol, 10 mM Hepes buffer (pH 7.64), 100 mM NaCl, and 3.75% ethanol in a 1.5 mL 
microcentrifuge tube.  The polymerization inducer molecule was arachidonic acid (ARA) at a 
concentration of 75 μM.  Reactions were allowed to proceed overnight at 25 °C. 
2.2.3 Thioflavin S fluorescence.  The total amount of aggregation was measured utilizing the 
thioflavin S (ThS) Sigma-Aldrich (St. Louis, MO) fluorescence assay. Thioflavin S binds 
amyloid structures in tau aggregates. Upon binding, thioflavin S undergoes a characteristic blue 
shift in its emission spectrum. It will not produce this blue shift upon binding to monomeric tau.  
150 μL of each reaction was added to separate wells in a 96-well, white, flat-bottom plate.  ThS 
was diluted in water and added to the well to a final concentration of 20 μM.  The fluorescence 
shift was measured with a Cary Eclipse Fluorescence Spectrophotometer (Varian Analytical 
Instruments, Walnut Valley, CA) with an excitation wavelength of 440 nm and an emission 
wavelength of 520 nm.  PMT voltage was set to 650 V.  Readings from a reaction with 2 μM 




2.3.4 Right-angle laser light scattering. Laser light scattering is a useful indirect method for 
measuring tau polymerization in vitro, in that under our conditions the intensity of scattering is 
proportional to the mass of polymerized tau filaments195. Aggregation of the protein was read by 
adding 180 μL of the reaction to a 5 mm x 5 mm optical glass fluorometer cuvette (Starna Cells, 
Atascadero, CA).  A 12 mW solid state laser, with a wavelength of λ=532 nm and operating at 
7.6 mW, was aimed at the cuvette.  The amount of light scattered by particles in the reaction was 
measured by capturing the amount of light perpendicular to the angle of the beam using a SONY 
XC-ST270 digital camera.  The images were captured at varying aperture settings (from f4 to 
f11) and analyzed using the histogram function of Adobe Photoshop195. 
2.3.5 ARA-induced polymerization kinetics.  ARA was added to our polymerization buffer 
(0.1 mM EDTA, 5mM dithiothreitol, 10 mM Hepes buffer (pH 7.64), 100 mM NaCl) to a final 
concentration of 75 μM and 3.75% ethanol in a 5 mm x 5 mm optical glass fluorometer cuvette.  
Tau polymerization was measured by collecting images of the right-angle scattered light at 
specific time points beginning from the initiation of the reaction upon addition of protein, at a 
final concentration of 2 μM, and the ending once the reaction had reached a steady-state.  The 
data were fit to the Finke-Watzky 2-step equation designed to describe the nucleation and 
elongation of protein aggregation196.  The mechanism assumes simplified nucleation (𝐴
𝑘1
→ 𝐵) 
and elongation (𝐴 + 𝐵 
𝑘2
→ 2𝐵) steps to yield the following equation: 











The k1 and k2 rate constants are used to qualitatively compare the rates of nucleation and 
elongation, respectively, of our protein aggregation reactions. [B]t is the aggregates formed over 
time t, [A]0 is the amount of monomeric tau at time zero and t is time in minutes.  
2.3.6 Transmission electron microscopy.  The ARA-induced polymerization reactions were 
diluted 1:10 in polymerization buffer and 2% glutaraldehyde.  After five minute incubation, a 
formvar-coated copper grid (Electron Microscopy Sciences, Hatfield, PA) was placed on top of a 
10 μL drop of the diluted sample for 1 minute.  The grid was then blotted on filter paper, placed 
on a drop of water, blotted with filter paper, placed on a drop of 2% uranyl acetate, and blotted 
dry.  The grid was then placed on another drop of 2% uranyl acetate for 1 minute and blotted dry 
for a final time.  For all tau variants a single grid was prepared and examined from each of three 
separate reactions.  The grids were examined using a TECNAI G2 20 electron microscope (FEI 
Co., Hillsboro, OR).  Images were collected with the Gatan Digital Micrograph imaging system 
at a magnification of 3600X.  Five images were collected from each grid and analyzed.  The 
aggregated tau in each of the 15 images was quantified by using Image-Pro Plus 6.0.  The macro 
was designed to recognize filaments with a total perimeter of greater than 30 nm.  This 
eliminated background noise.  The perimeter of each filament was measured and divided by two 
in order to estimate the filament’s length.  These values were totaled in order to estimate the total 
amount of aggregated material in each image.   The total polymerization/image was calculated 
by taking the mean of all total polymerization values.  The mean of all filament lengths was also 
determined by calculating the mean length of all filaments in a given image and reported as a 
mean of those values with the error bars representing standard deviation.   
2.3.7 Tubulin polymerization assay. Microtubule polymerization was monitored by recording 
the DAPI fluorescence enhancement due to the incorporation of a fluorescent reporter into 
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microtubules as polymerization occurs. The Tubulin Polymerization Assay kit from 
Cytoskeleton, Inc. (Denver, CO) was used to measure the polymerization of tubulin.  The 
reaction conditions included WT tau or one of the tau variants at 1 μM, or a control compound, 
added along with 1 mM GTP, 2 mg/ml (~36 μM dimerized) tubulin, 2 mM MgCl2, and 0.5 mM 
EGTA in 80 mM PIPES buffer at a pH of 6.9.  The reaction proceeded in a black, flat-bottomed 
polystyrene 96-well plate.  Paclitaxel was used at 3 μM in one reaction to serve as a positive 
control for tubulin polymerization, as well as a way to normalize separate reactions. One well 
containing no compound served as a negative control.  After addition of the compounds the plate 
was inserted into a FlexStation II Fluorometer (Molecular Devices Corporation, Sunnyvale, CA) 
set at a temperature of 37 °C and the reactions were mixed by shaking for 5 seconds.  The 
fluorescence was measured with an excitation wavelength of 355 nm and an emission 
wavelength at 455 nm at 1 minute intervals for 1 hour.  The data were fit to the Gompertz 
equation 
y = ae –e [(t-ti)/b)] 
as described previously 86.  y is the value of laser light scattering measured at time t; a is the 
maximum amount of light scattering; ti is the point of inflection where the increase in scattering 
is at its maximum and b is equal to 1/kapp. Kapp is proportional to the rate of polymerization. 
These values were averaged and reported ± standard deviation14, 86. 
2.3.8 Statistical analysis.  An unpaired two-tailed Student’s t-test was used to compare means of 
WT values to mean values of each tau truncation mutant for Thioflavin S fluorescence, right-
angle laser light scattering, quantitative electron microscopy, kinetics parameters and for the 
microtubule assembly assay.  P-values less than or equal to 0.05 are indicated with one asterisk 
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(*), less than or equal to 0.01 with two asterisks (**), and less than or equal to 0.001 with three 
asterisks (***).   
2.3 Results 
2.3.1 Selection of truncation mutants. Tau is known to be truncated at both its termini during 
the progression on Alzheimer’s disease. We generated eight different tau truncation mutants 
consisting of two carboxyl- terminal truncation mutants, five amino-terminal truncation mutants 
and one mutant with truncations at both the amino and carboxyl termini. The truncations are 
shown in figure 2.2.  
2.3.2 Tau truncation mutants have variable effects on the total polymerization  In vitro 
experiments were done to examine the effects of the truncation mutants on the ARA-induced 
polymerization of tau at 2 μM protein and 75 μM ARA. After the reactions proceeded overnight, 
the total amount of aggregation was measured by ThS fluorescence and right-angle laser light 
scattering (LLS). In the ThS assay, most of the truncations decreased the total amount of tau 
aggregation compared to the WT except for 43-441. Among those which showed a decrease, 
truncation 81-441, 201-441, 256-441 and 256-391 showed a significant decrease in 


























































































































Figure 2.3: Polymerization of wild-type and tau truncations measured by Thioflavin S 
binding and right-angle laser light scattering. Polymerization reactions contained 2 μM of 
WT or one of 8 tau truncations and 75 μM ARA. Reactions were incubated overnight at 25° C. 
The final extent of polymerization was measured by (A) ThS fluorescence and (B) right-angle 
LLS. Data represent the mean from 5 experiments ±SD. Stars represent P-value results from 
Student’s unpaired t tests comparing means from each mutant to WT. (*), P < 0.05; (**), P < 





In the LLS assay, 14-441, 43-441, 81-441, and 1-391 showed a decrease in the amount of 
polymerization compared to WT (Figure 2.3 B). We were unable to quantify the LLS values for 
aggregation by 201-441, 256-441 and 256-391 because the aggregates did not scatter light evenly 
(Figure 2.4). Upon doing electron microscopy, there were no detectable filaments on the electron 
microscopy grids of mutants 201-441, 256-441 and 256-391. We therefore speculate that the 
light scattering could be due to micelles formed by ARA due to its interaction with the 
constructs. This does not rule out the possibility of presence of very large aggregates which 
could be affecting the light scattering. Also, the protein could be precipitating and forming 
amorphous clumps of the protein and not be forming ordered filaments as in the case of tau 
aggregates. Further investigation to determine the exact nature of interaction between ARA and 
these constructs would help in explaining the uneven light scattering observed.  
Based on the LLS and ThS results, we believe that N- terminal truncations with more than 80 
residues truncated, are reducing the total amount of aggregation and the C-terminal truncations 
are not causing a decrease in the total amount of aggregation. While the removal of the N- and 
C- termini of tau together, leaving only the PHF fragment, leads to a significant decrease in the 








Figure 2.4  
 
Figure 2.4 LLS images. These are images of LLS assay for 14-441, 201-441, 256-441 and 256-
391. The light is scattered evenly for 14-441. This can be quantified using the histogram function 
in Adobe Photoshop. The light is scattered in an uneven fashion for 201-441, 256-441 and 256-













Figure 2.5 Electron micrographs of polymerization reactions containing 2 μM protein and 
75 μM ARA. Representative electron micrographs for WT, 14 – 441, 43 – 441, 81 – 441, 201 
– 441, 256 – 441, 1 – 391, 1 – 421 and 256 – 391. The scale bar in the lower right panel 



















































































































Figure 2.6: Quantitation of polymerized tau protein in electron micrographs. Images in 
the electron micrographs from Figure 2 were quantified using Image-Pro Plus 6.0. (A) The 
graph displays the total length (nm) of polymerized tau filaments/image. (B) The graph 
displays the average filament length (nm) of polymerized tau filaments/image. Data in both 
graphs represent the mean of 5 images from each of 2 separate reactions ±SD for a total of 
n=10. Stars represent P-value results from Student’s unpaired t tests comparing means from 





2.3.3 Tau truncation mutants have little effect on tau filament morphology. LLS and ThS 
are both very informative assays but are indirect methods of quantifying tau aggregation. The 
LLS results are affected by the length distribution of the aggregates and the structure of tau 
recognized by ThS is not known as yet. Therefore, we viewed the filaments directly by electron 
microscopy (Figure 2.5). The morphology of the filaments of the 14-441, 43- 441, 81-441, 1-391 
and 1-421 truncation forms looks similar to the WT filaments. There were no detectable 
filaments on the electron microscopy grids of mutants 201-441, 256-441 and 256-391. Earlier, 
we saw a significant decrease in ThS staining for these three truncations (Figure 2.3A).  
We quantified the total filament lengths (total tau aggregation) and the average filament lengths 
of the aggregates on the grids (Figure 2.6). The total tau aggregation by the N-truncation mutant 
81-441 was significantly lower than that of WT tau. The average filament length of 81-441 was 
also significantly lower than that of WT. The 1-391truncation caused an increase in the total tau 
aggregation compared to WT tau and a decrease in the average filament length.  
1-421 did not have an effect on the total amount of tau aggregation compared to the WT but 
showed a significant decrease in the average filament length. The other mutants, 14-441 and 43-
441 caused an overall slight decrease in filament length compared to WT. 14-441 made filaments 
which were slightly longer than the wild type tau filament lengths.  
2.3.4 Kinetics of polymerization varies with the tau truncation mutants. The morphology of 
the tau aggregates could be influenced by the rate of polymerization. We therefore sought to 
determine if the tau truncations are affecting the rate of polymerization. The polymerization was 
followed using LLS and the numbers were then fit to a two-step model of polymerization to 
determine the nucleation and the elongation rates (Figure 2.7). As mentioned earlier, the 
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aggregates of tau truncations 201-441, 256-441 and 256-391 did not scatter light evenly and 
therefore it was not possible to carry out aggregation kinetics study on these.  
We compared the nucleation rates of these mutants (Figure 2.8). 1-391, 1-421, 43-441 and 81-
441 truncation mutants showed a significantly higher nucleation rate than the WT. While the 
nucleation rates of 14-441 did not differ much from that of the WT. The elongation rates of the 
truncations 1-391, 1-421, 43-441 and 81-441were significantly higher than that of the WT.  
The N truncation mutants had an overall lower amount of tau aggregation at the end of 6 h 
compared to the WT, while the C-truncation mutants were closer to the WT in terms of total 
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Figure 2.7 Comparison of tau polymerization kinetics. The parameters describing the tau 
polymerization kinetics curves fit to the Finke-Watzky mechanism are displayed. The first 
parameter is (A) k1, representing the rate of nucleation or formation of oligomers. The 
second parameter is (B) k2, the rate of elongation or extension of the oligomeric tau 
aggregates into filaments. Data represent means of values for fits of at least 3 separate 
reactions ±SD. Stars represent P-value results from Student’s unpaired t tests comparing 



















































































































Figure 2.8: Comparison of tau polymerization kinetics. The parameters describing the tau 
polymerization kinetics curves fit to the Finke-Watzky mechanism are displayed. The first 
parameter is (A) k1, representing the rate of nucleation or formation of oligomers. The 
second parameter is (B) k2, the rate of elongation or extension of the oligomeric tau 
aggregates into filaments. Data represent means of values for fits of at least 3 separate 
reactions ±SD. Stars represent P-value results from Student’s unpaired t tests comparing 





2.3.5 Tau truncations have differing effects on tau’s ability to stabilize microtubule 
assembly. We sought to determine whether the tau truncations would affect tau’s normal 
function of stabilizing microtubules. Microtubule polymerization was monitored using a 
fluorescence-based assay and the resulting curves (Figure 2.9) were fit to a Gompertz function in 
order to determine maximal extent of microtubule polymerization, the rate of elongation, and lag 
time in the presence of the tau truncations (Figure 2.10). Most of the proteins stabilized 
microtubules (MTs) to levels similar to WT tau. 256-441 and 1-391 stabilized MTs to a lesser 
extent compared to WT tau. 256- 391 reduced the overall MT stabilization significantly. 256-
391, 1-391 and 256-441 induced MT elongation at a slower rate. The lag time for tubulin 
polymerization was increased in the presence of 256-391 and 256-441 while 14-441 and 81-441 
slightly decreased the lag time.  
2.4 Discussion  
In AD, monomeric tau undergoes a complex series of posttranslational modifications such as 
phosphorylation, acetylation etc. followed by enzymatic cleavages, and conformational changes 
that lead to transformation of monomeric soluble tau to an insoluble accumulation of misfolded 
protein. Truncation is an important post-translational modification having an etiological role in 
tau pathology. The truncation state of tau protein affects many of tau’s normal and pathologic 
characteristics such as its ability to bind to microtubules, to assume specific conformations and 
its ability to self-assemble to form tau filaments. We sought to directly compare aggregation and 




The first evidence of tau’s change in conformation was obtained when the discontinuous 
epitopes of the Alz50 and tau-66 monoclonal antibodies were discovered41. 
Alz50 identifies the conformation of tau when its amino terminus comes in contact with the 
MTBR region, making a compact conformation which converts the soluble random coil 
configuration of tau into a more compact conformation which facilitates aggregation. The Alz50 
conformation as mentioned earlier, is seen in early pre-tangle tau. Later in AD, tau molecule in 
Alz-50 conformation can shift to the tau-66 conformation which basically depends upon the 
proline-rich region (155-244) of tau interacting with a region of the MTBR (305-314), which 
partially overlaps the putative N-terminus binding site in the Alz-50 conformation197 (Figure 
2.1). 
We made five truncation mutants of tau with varying lengths of N-terminal truncations (Figure 
1). The removal of portions of the N-terminal will affect the Alz-50 and tau 66 conformations 
and therefore should have an impact on tau aggregation. Truncation at N –terminal a.a. site 13, 
did not change the tau aggregation kinetics compared to WT tau. The N –terminal epitope 
involved in Alz50 is a.a.2-18. Therefore, the truncation at D13 site does not completely eliminate 
this epitope and therefore a weakened Alz50 conformation can be formed.  
Upon truncating larger portions of the N-terminus by making truncations at 42 and 80 we 
observed an increase in the rate of tau aggregation. The elimination of larger portions of tau N –
terminus may be driving the tau monomers to form the tau-66 conformation, without going 







Figure 2.9: Microtubule assembly curves in presence of tau. Each point represents a mean 
value of the amount of tubulin polymerized into microtubules in the presence of wild-type tau 
(black) or tau truncations of (A) 14-441, (B) 43-441, (C) 81-441, (D) 201-441, (E) 256-441, 
(F) 1-391, (G) 1-421 and (H) 256-391. The values are fluorescence readings normalized to 
paclitaxel-stabilized polymerization of microtubules. 
 
 





Further truncations at a.a. 200 and a.a. 256 eliminates the proline-rich region of tau molecule 
required for the formation of tau 66 conformation. These mutants may therefore not form either 
of the two Alz50 and tau66 conformations. We observed that these truncation mutants were 
unable to form tau filament when observed under electron microscope. Based on these results we 
may infer that formation of either the alz50 or the tau 66 conformation may be required for 
formation of tau filaments.  
The 81-441 truncation gets rid of the N-terminal hydrophobic region (a.a. 75VTAPLV80). This 
truncation reduced the overall amount of aggregation and increased the filament nucleation and 
elongation rates significantly. This could mean the fast nucleation is taking up large amounts of 
monomeric tau quickly and leading to a drop in the protein level below the critical concentration 
of aggregation required for the elongation step. This was reflected in the significant reduction in 
the average filament lengths compared to the WT tau filament lengths. 
The N-terminal and the proline-rich domains play a major role in the conformational changes in 
tau required for formation of tau filaments. We observed that none of the N-terminal truncations 
in our study cause an increase in aggregation. Therefore N-terminal truncations may not be 
initiating aggregation but may be playing a role in the later stages of pathogenesis after 
formation of tau aggregates. We have included only five N –truncation mutants in our study. A 
recent study has identified 21 new N –terminally truncated tau species that occur in the human 
brain. Their findings suggest that the N-terminal part of tau could be directly involved in 
regulation of microtubule stabilization151. It would be interesting to test whether these 























































































































































































Figure 2.10: Stabilization of microtubule assembly by tau protein. The tau truncation 
mutants were incubated with tubulin and its polymerization was measured via a fluorescence 
assay. Numbers were normalized to values of polymerization in the presence of paclitaxel. 
The relative fluorescence units (y-axis) were plotted vs. time (x-axis) and fit to the Gompertz 
equation. From the parameters describing these curves, the values normalized against that of 
WT for the (A) maximum amount of microtubule polymerization in presence of each protein, 
(B) kapp or rate of microtubule polymerization, and (C) lag time, the time before microtubule 
polymerization is detected. The values in (A–C) are mean values of the changes from WT in 
three separate experiments ±SD. Stars represent p-value results from Student’s unpaired t 







We made two constructs with truncations at the carboxyl terminal 1-391 and 1-421. Truncations 
at D421 and E391 allow for the formation of alz50 and the tau66 conformations. In our 
experiments, both these truncations reduced the average filament length compared to those 
formed by WT full length tau. The nucleation and elongation rates for both the truncations were 
significantly higher than that of WT. The 1-391 truncation showed a significant increase in the 
total amount of aggregation and showed a significant reduction in average filament lengths. We 
have used the Finke-Watzky mechanism and feel it is a good way to calculate the nucleation and 
elongation rates in a simplified manner to accurately represent the differences in aggregation 
mechanisms for the truncation constructs. Tau truncations at the C-terminal assemble at a faster 
rate than WT tau100. Truncations at E391 and D421 are known to occur in AD.  Truncation at 
E391 is known to occur fairly late in AD. The D421 truncation is brought about by caspase 6 
after the formation of NFTs97. The expression of a truncated tau molecule consisting of a.a. 151-
421 in hippocampal neurons induced apoptosis suggesting that caspase cleavage at D421 turns 
tau into an apoptosis effector molecule. The longest fragment with full apoptotic capacity is tau 
l-422, which only lacks the 19 C-terminal residues198. The relationship between tau aggregation 
and its apoptotic properties is presently unclear.  
C-terminal truncations therefore have the ability to induce aggregation and therefore may occur 
at the early stages or the later stages of tau aggregation. Our data does not provide evidence that 
truncation initiates tau aggregation. It would be interesting to conduct experiments to test the 
same by doing tau aggregation reactions without ARA but using a small amount of 1-391 or 1-
421 aggregates which may sequester full length tau protein to form aggregates.  
In AD, tau is eventually truncated at both its N- and C- terminal. Therefore we created a 
construct with only 256-391, which approximates the PHF core region193. There was a 
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significant decrease in the total amount of tau aggregation and the EM grids didn’t show any 
filaments formed. The LLS assay could not be quantified for the same reason as for 201-441 and 
256-441 constructs discussed previously. In previous studies, K19 tau construct has been used to 
accelerate tau filament formation drastically. K19 also approximates the PHF core region, but it 
is made from 3-repeat tau isoform and therefore is missing the second microtubule binding 
repeat (exon 10)199. Tau filament assembly proceeds at a more rapid rate if the protein subunits 
are cross-linked into dimers, for example by an oxidized disulfide bridge ay Cys 322. In the case 
of K19 construct, there is a single Cys 322. This will form dimers with other K19 monomers 
easily and therefore form dimers which will help accelerate aggregation. In our construct, we 
have two cysteine residues at positions 291 and 322. Therefore, there is a greater possibility of 
intramolecular bonds being formed between these cysteine residues, which would make them 
unavailable for dimerization. This would limit the formation of tau dimers and therefore will 
inhibit tau filament formation. This could explain the decrease in tau aggregation for 256-391 
truncation mutants we saw in our assays. It would be interesting to have a mixture of K19 and 
256-391 mutants and observe the tau aggregation kinetics and filament morphology.   
The other effect of tau aggregation is loss of MT binding. We therefore, tested the ability of the 
truncated tau species to polymerize MT assembly. The N-terminal truncations did not differ from 
the WT full-length tau in their ability to polymerize MTs. The 256-441 showed a decrease in the 
total amount of MT polymerization. There was a significant decrease in the rate of MT 
polymerization and an increase in the lag time, which is basically the nucleation time for tubulin 
in MT assembly process. This could be because the 256-441 truncation eliminates the proline-
rich region as well as part of the first MTBR region. The C- terminal truncations had different 
effects on MT polymerization compared to WT. The maximum amount of MT polymerization 
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was not different from that in presence of WT tau. 1-391 had a reduced rate of MT 
polymerization compared to WT. This can be explained by the possibility of masking of the 
MTBR region by the N terminal. The 256-391 truncations significantly decreased the maximum 
amount of MT polymerization, the rate of MT polymerization and showed an increase in lag 
time. Table 2.11 summarizes the observed results and the predicted effects on tau conformations. 
FTDP-17 mutants like R5L have shown to enhance tau aggregation under similar experimental 
conditions200. They aggregate into longer tau filaments compared to WT and a lack of oligomeric 
tau species. The first 25 amino acids of tau protein carry a charge of -4 while the charge on the 
third MTBR is +3. Due to the R5L mutation, the overall charge of the amino region changes 
from -4 to -5, and possibly increases the electrostatic interaction between the N –terminus and 
MTBR. This means that changes in the charge of specific amino acids placed at strategic 
positions on tau protein involved in conformational changes required for aggregation affect the 
protein aggregation properties to a larger extent than making changes like truncation of a stretch 
of 14 to 50 residues at once.  
Extensive studies on the effects of C-terminal tau truncation in vivo have been done95. We now 
know that the tau truncation at the N-terminal is a regulated process with several preferential 
cleavage sites within the tau molecule and is not a random process191. Studies using rat brain 
tissue have shown that transgenic truncated tau is sufficient to initiate and drive the tau 
truncation cascade. These truncation models have been studied individually and their effects 
have been studied in vitro and in vivo. This is the first study where in a wide range of tau 
truncations including N-terminal, C-terminal as well as a construct with truncations at both the 
termini have been compared and studied under similar experimental conditions.  
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We saw a clear difference in the effects of N-terminal truncations compared to those of C-
terminal truncations on tau aggregation and MT assembly. These effects correlated well with the 
ability of the truncations to form alz50 and/or the tau 66 conformations. Truncations which 
inhibited formation of both these conformations were unable to form tau filaments. The site of 
truncation on either of the terminals also affects the aggregation kinetics and MT assembly 
parameters. Further characterizing of truncation mutants and their effects in animal models or 
other in vivo systems may help explain the role played by tau truncations in tauopathies and how 



















      Tau 66 
 
 
Tau aggregation  
 




(Compared to  














































filaments seen on 
electron microscopy 
grids. 
Decrease in rate and 
total amount of MT 
polymerization. 






















Tau aggregation  
 


























filaments seen on 
electron microscopy 
grids. 
Decrease in rate and 
total amount of MT 
polymerization. 
Increased lag time. 
 
Table 2.2 This table summarizes conformational possibilities for each of the truncation mutants. 










Chapter III  Tau aggregation inhibitors obtained from Aspergillus nidulans: First 
generation compounds  
3.1 Introduction  
Alzheimer’s disease (AD) is the most common form of dementia. It is a neurodegenerative 
disease characterized by pathological markers – mainly intracellular tau aggregates and 
extracellular amyloid plaques. The physiological role of tau protein is to regulate microtubule 
stability by binding to microtubules. In the diseased state however, tau undergoes post 
translational modifications and undergoes conformational changes which result in its dissociation 
from microtubules201. The dissociated tau aggregates into different types of inclusions such as 
neurofibrillary tangles , neuropil threads and neuritic plaques. These inclusions are found in AD 
and in several other neurodegenerative tauopathies92. Mutations in the tau gene have been 
associated with tauopathies such as FTDP-17 (Frontotemporal dementia with parkinsonism 
linked to chromosome 17)200. Tau aggregation correlates well with the type and severity of 
cognitive impairment in AD42 and tau aggregation can lead to cell death and cognitive defects in 
cellular and animal models43.  Therefore, tau aggregation is a viable therapeutic target for 
treatment of AD and other tauopathies.  
Tau aggregation involves confortational changes in tau molecules and these tau molecules 
interact with each other to form tau filaments. The core of the tau filaments is made of β-sheet 
strucures and it is believed that small molecules that intereact with these β sheet structures inhibit 
tau aggregation by potentially preventing further addition of tau molecules to the growing 
aggregate44, 202. Compounds belonging to the class of polyphonols162, cyanine dyes176, 
phenothiazines162, rhodanine168 , N-phenylamines203, thienopyridazines177, quinoxalines204 and 
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anthraquinones166 have been previously identified as tau aggregation inhibitors. These 
compounds belong to different classes but share the common feature of having multiple aromatic 
fused-rings in their structure. These compounds are in their initial stages of discovery and 
therefore it is not known whether they would be effective in vivo or whether they have the 
required pharmacokinetic properties and can cross the blood brain barrier. Is it necessary to find 
more lead compounds which could inhibit tau aggregation and would be suitable for further 
development.  
Fungi have historically been a good source of medicinally important compounds such as 
antibiotics, antioxidants and antimicrobials. Using efficient gene targetting systems, Dr. Berl 
Oakley’s lab along with their collaborators have identified many biosynthetic pathways 205-207in 
Aspergillus nidulans that produce compounds with a wide range of chemical structures208-215. 
Some of these compounds share structural similarities with previously identified tau aggregation 
inhibitors such as the presence of fused ring structures. We decided to determine if these 
compounds also inhibited tau aggregation. We chose 17 compounds which included 
anthraquinones, xanthones and other metabolites and assessed their ability to inhibit tau 
aggregation in vitro. Several compounds affected tau filament assembly at various levels. 
Amongst these three compounds, asperthecin, asperbenzaldehyde and 2, ω-dihydroxyemodin 
were potent and gave reproducible results in inhibiting tau aggregation in a dose dependent 
fashion. The compounds did not completely inhibit tau’s function of stabilizing microtubules. 
These compounds are therefore good candidate compounds for further development. Two of the 
compounds – asperthecin and 2, ω- dihydroxyemodin belong to the anthraquinone class of 
compounds. Some of the compounds belonging to this class have previously been identified as 
tau aggregation inhibitors (TAIs)166. Asperbenzaldehyde was an interesting compound because it 
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has a novel structure compared to previously identified TAIs. Further, it is an intermediate in an 
azaphilone biosynthesis pathway. Azaphilones are compounds with interesting biological 
activities which includes lipoxygenase inhibitor activity, which is a beneficial property for 
treatment of AD211. 
3.2 Experimental procedures 
3.2.1 Compounds. Compounds were purified from Aspergillus nidulans as described 
previously211, 213-217 from a single peak of HPLC chromatography, and purity was estimated by 
NMR (Table 3.1). 
3.2.2. Tau polymerization reactions. 2 µM recombinant tau protein was incubated in 
polymerization buffer which contained 10 mM HEPES (pH 7.64), 5 mM DTT, 100 mM NaCl, 
0.1 mM EDTA, and 3.75 % ethanol. Compounds dissolved in DMSO were added to the tau 
solution at final concentrations of 200 µM, 100 µM, 50 µM, or 25 µM as described in Results. 
Compounds were allowed to incubate with tau for 20 min before the addition of 75 µM 
arachidonic acid to initiate tau filament formation 218. The reactions were allowed to proceed at 









Table 3.1. Purity of tested compounds from 1H NMR spectra (Prisinzano lab, KU) 
Compound name Integration of impurity in 1H 
NMR 
Estimated purity 
A. Emericellin 0.17 > 85 % 
B. Variecoxanthone 0.08 > 92 % 
C. Emodin 0.06 > 94 % 
D. 2,ω-Dihydroxyemodin 0.06 > 94 % 
E. Endocrocin 0.05 > 95 % 
F. Sterigmatocystin 0.04 > 96 % 
G. F9775A 0.13 > 88 % 
H. F9775B 0.05 > 95 % 
I. Asperthecin 0.04 > 96 % 
J. Crysophanol 0.06 > 94 % 
K. Aloe emodin 0.06 > 94 % 
L. Shamixanthone 0.07 > 93 % 
M. Demethylsterigmatocystin 0.02 > 98 % 
N. ω-Hydroxyemodin 0.06 > 94 % 
O. Monodictyphenone 0.24 > 80 % 
P. 3-hydroxyversiconol 0.03 > 97 % 




3.2.3. Filter trap assay. Tau polymerization reactions, as described above, were diluted to 
20 ng/300 µL in TBS and passed through a pre-wetted nitrocellulose membrane (Bio-Rad 
Laboratories) using vacuum force in a dot-blot apparatus (Bio-Rad Laboratories). The 
membranes were washed thrice with TBS-0.05 % Tween20 (TBST) and then blocked in 5 % 
nonfat dry milk in TBST for 1 h. The membranes were then incubated with a mixture of three 
primary antibodies overnight at 4 °C [Tau 5 antibody219 at 1 : 50 000 dilution, Tau 12 antibody96 at 
1 : 250 000 dilution, and Tau 7 antibody192 at 1 : 250 000 dilution; antibodies were a kind gift from 
Dr. Lester I. Binder]. Membranes were washed thrice in TBST and incubated with secondary 
antibody, [HRP-linked goat anti-mouse IgG (Thermo Scientific)], for 1 h. at room temperature. 
The membranes were washed twice in TBS-Tween buffer, and a final wash was made with TBS. 
The blot was developed using an ECL (enhanced chemiluminescence) Western blotting analysis 
system (GE Healthcare). Images were captured with a Kodak Image Station 4000R and were 
quantified using the histogram function of Adobe Photoshop 7.0. Statistical analyses were 
performed using 1-way ANOVA with Dunnettʼs multiple comparison test to compare the 
triplicate values to control values. 
3.2.4 Transmission electron microscopy. Polymerization reaction samples were diluted 1 : 10 in 
polymerization buffer and fixed with 2 % glutaraldehyde for 5 min. 10 µL of each sample was 
added to a Formvar carbon-coated grid for 1 min. The grid was blotted on filter paper, washed 
with water, blotted, washed with 2 % uranyl acetate and blotted before staining with 2 % uranyl 
acetate for 1 min. followed by a final blotting on filter paper. The grids were examined with a 
Technai F20 XT field emission transmission electron microscope (FEI Co.). Images were taken 
with the Gatan Digital Micrograph imaging system. The images were collected at a 
magnification of 3600×. The filaments were quantified using Image-Pro Plus 6.0 software 218. 
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The perimeter of the filaments was determined, and the length was obtained by dividing the 
perimeter in half. For quantitative analysis, filament lengths were placed into bins as described in 
Results. Statistical analyses were performed using two-way ANOVA with Bonferroni post-tests 
to compare replicate means for each bin size with the no compound data serving as reference 
values. 
3.2.5 Tubulin polymerization assay. Polymerization of tubulin was measured using a tubulin 
polymerization assay kit (Cytoskeleton, Inc.). Microtubule polymerization was monitored by 
recording the DAPI fluorescence enhancement due to the incorporation of a fluorescent reporter 
into microtubules as polymerization occurs in presence or absence of compound.  The reactions 
were measured in 96-well Costar black polystyrene flat-bottom plates (Corning, Inc.). Each well 
contained porcine tubulin at 2 mg/mL and GTP at 1 mM in 80 mM PIPES buffer (pH 6.9) with 
2 mM MgCl2 and 0.5 mM EGTA. Tau was added to the wells at a concentration of 1 µM, and the 
test compounds diluted in DMSO were added at a final concentration of 200 µM. An equal 
amount of DMSO was added to each of the wells. Another well containing 1 µM paclitaxel 
(99.1 % pure; Cytoskeleton, Inc.) and tubulin served as a positive control for polymerization and 
as a standard for normalizing results for each of the experiments (not shown). Control reactions 
containing only buffer without either tau or a compound, and buffer with the individual test 
compounds but without tau were also performed (not shown). Reaction plates were placed at 
37 °C and shaken for 5 s in a FlexStation II fluorometer (Molecular Devices Corp.). The 
fluorescence was measured at a constant interval of 1 min. for 1 h. with an excitation wavelength 
(λex) of 355 nm and an emission wavelength (λem) of 455 nm. This gave 60 readings for every 
well sample. The resulting data were normalized to the amount of microtubule polymerization 
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observed in the presence of tau without a compound and fit to the Gompertz equation218. 
Experiments were performed in triplicate and averaged.  
3.3 Results 
3.3.1 Compounds used in this study. We chose 16 compounds obtained from Aspergillus 
nidulans based on their structural similarity to previously identified tau aggregation inhibitors 
and one of our compounds had a different chemical structure compared to the others. 8 
compounds belong to the group of anthraquinones, five are xanthones and four compounds are 
other types of metabolites. These can be divided as compounds with mutiple fused-ring 
structures of monocyclic aromatic compounds (Figure 1). Emodin, among these compounds has 
been identified as an inhibitor of tau aggregation in a previous study166. 
3.3.2. Compounds inhibited tau aggregation at 200 μM. Tau aggregation was initiated in vitro 
using a standard arachidonic acid induction protocol218. Each compound was incubated with tau 
for 20 mins before inducing aggregation using arachidonic acid. The final concentration of each 
compound in the reactions was 200 μM. The protein concentration was 2 μM and that of 
arachidonic acid was 75 μM in all the assays. The amount of aggreation was determined using 








Figure 3.1  
 
Figure 3.1 Compounds used in this study. Compounds used in this study. (A–Q) Structures of 
the 17 compounds used in this study: (A) Emericellin, (B) Variecoxanthone, (C) Emodin, (D) 
2,ω- dihydroemodin, (E) Endocrocin, (F) Sterigmatocystin, (G) F9775 A, (H) F9775 B, (I) 
Asperthecin, (J) Chrysophanol, (K) Aloe emodin, (L) Shamixanthone, (M) 
Demethylsterigmatocystin, (N) ω – hydroxyemodin , (O) Monodictyphenone, (P) 3’- 
Hydroxyversiconol and (Q) Asperbenzaldehyde.  
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3.3.2.1. Filter trap assay. There was a decrease in tau aggreation seen in the presence of 
variecoxanthone, 2,ω-dihydroxyemodin, sterigmatocystin, asperthecin, chrysophanol, 
endocrocin, asperbenzaldehyde and shamixanthone (Figure 3.2). Among these, 2,ω-
dihydroxyemodin, asperthecin, asperbenzaldehyde and chrysophanol showed a significant 
decrease in aggregation compared to the control reaction with no compound. Emodin, which has 
previously been shown to inhibit tau aggregation in vitro166, did not show inhibition in our 
assays. The inducer molecule used in a previous emodin study was the glycosaminoglycan 
heparin , which is not as potent as arachidonic acid in inducing aggregation218. Further, the tau 
isoform used in the previous study was not the full length tau. These differences could account 
for the difference in activity seen for emodin. This is discussed in more detail in the discussion 
section of this chapter.   
3.3.2.2 Transmission electron microscopy. The filter trap assay is very informative, but it is an 
indirect method of quantifying tau aggregation. The results are affected by the ability of 
nitrocellulose membrane to retain certain types or size of the tau aggreates. Therefore, we viewed 
the filaments directly by transmission electron microscopy.  Asperthecin, asperbenzaldehyde, 
sterigmatocystin and 2,ω-dihydroxyemodin were the most effective compounds in inhibiting tau 
filament formation compared to the control reaction where no compound was added (Figure 3.3). 
     We further analysed the filament lengths in presence and absence of the compounds. We 
measured the filament lengths and placed them in 50 nm bins ranging from 30 nm to 200nm. The 
first bin was 30nm-50nm, because anything less than 30 nm is diffficult to distinguish from the 
electron microscope grid background and therefore makes it difficult to measure. We placed all 
the filaments above 200nm in one group because this cutoff should represent particles retained 

















































































































































































































Filter trap assay of tau filament formation. The compounds used are listed on the Y-axis. The 
values for tau polymerization were normalized to the amount in the no compound control (dotted 
line). Negative values indicate that there was less detectable tau on the filter after treatment with 
a compound than was observed with monomeric tau in the absence of arachidonic acid. Values 








Emodin, variecoxanthone, F9775A, endocrocin, F9775B, asperthecin, emericillin, 2,ω-
dihydroxyemodin, sterigmatocystin, aloe emodin, monodictyphenone, ω-hydroxyemodin and 
asperbenzaldehyde had filaments length distributions distinct from those of the no compound 
control (Figure 3.4). Asperbenzaldehyade had the most effect on the filament lengths with no 
filaments detected above 100nm in length.  
       Many of the compounds decreased the amount for tau aggreation which suppports our 
rationale for choosing this set of compounds. Among all the compounds, asperthecin, 
asperbenzaldehyde and 2,ω-dihydroxyemodin showed reduction in aggregation in both the filter 
trap assay as well as the in electron microscopy.  
3.3.3  Three compounds showed a dose-dependent activity. We sought to determine whether 
these compounds inhibit tau aggreation in a dose-dependent fashion. Therefore, we did dose-
dependent tau aggregation inhibition assays for asperthecin, asperbenzaldehye, 2,ω-
dihydroxyemodin and sterigmatocystin. Sterigmatocystin sometimes showed dose dependent 
inhibiton activity but these data were not reproducible (data not shown), therefore the IC50 value 
could not be determined. The other three compounds gave reproducible dose dependent 
inhibition results. The IC50 values for asperthecin, asperbenzaldehyde and 2,ω-dihydroxyemodin 


























Figure 3.3. Electron microscopy of tau filament formation in the presence of compounds.  
Tau polymerization reactions were performed with 2 μM tau and 75 μM arachidonic acid either 
with or without 200 μM compound. Aliquots of the reactions were prepared for negative stain 
electron microscopy. Representative images are shown for no compound control and compound 
treatment reactions (A-Q) (A) emericellin, (B) variecoxanthone, (C) emodin, (D) 2,ω-
dihydroxyemodin, (E) endocrocin, (F) sterigmatocystin, (G) F9775A, (H) F9775B, (I) 
asperthecin, (J) chrysophanol, (K) aloe emodin, (L) shamixanthone, (M) 
demethylsterigmatocystin, (N) ω- hydroxyemodin, (O) monodictyphenone, (P) 3’- 
hydroxyversiconol and (Q) asperbenzaldehyde. The scale bar in the lower right panel represents 

















Figure 3.4  































































































































































































































































































































































































































Figure 3.4. Filament length distributions. Filament lengths from electron micrographs of tau 
polymerization reactions were measured, placed into 50 nm bins (30–50 nm, 50–100 nm, 100–
150 nm, 150–200 nm and > 200 nm), and the lengths were summed to determine the total amount 
of filament length in each bin. The first graph (A) shows the control reaction without a 
compound, and graphs B-R show the reactions with the different compounds, being labeled with 
the compound name and number. The filament distribution for the no-compound control is 
redrawn on each graph as a light gray line for comparison. Each point is the average distribution 






































 IC50 determination tau filament assembly. Polymerization reactions at 2 µM tau and 75 µM 
arachidonic acid were performed at several different concentrations of the compounds, and the 
resulting amount of tau filaments in the reaction was determined by a filter trap assay detected by 
a mixture of antibodies to normal tau (tau 5, tau 7, and tau 12). The amount of polymerization 
was normalized to controls in the absence of compound (100%). The normalized data was 
plotted against the log of the inhibition concentration and fit to a dose–response curve to 
determine the IC50 for asperbenzaldehyde (blue), 2, ω- dihydroxyemodin (red), asperthecin 
















Figure 3.6 Microtubule assembly. Tubulin was incubated with either tau protein alone (black) 
or tau in the presence of (A) 2,ω-dihydroxyemodin, (B) asperthecin, or (C) asperbenzaldehyde 
at compound concentrations of 50 µM (blue) or 100 µM(red). Microtubule assembly was 
monitored by DAPI fluorescence (y-axis) over time (x-axis) and normalized to microtubule 
polymerization in the presence of paclitaxel. Every third time point is shown. Each point is the 
average of three independent trials ± SD. The data are fit to a Gompertz growth curve (black, 

















Table 3.2 Statistical analysis of the effects of anti-tau aggregation compounds on the 
stabilization of microtubules. 
 
Asperbenzaldehyde a b ti 
No compound 0.96 ± 0.02 4.2 ± 1.2 4.8 ±1 .5 
50 μM 0.93 ± 0.01 4.1 ± 1.0 5.4 ± 1.2 
100 μM 0.72 ± 0.04*** 7.9 ± 2.3 10.2 ± 2.7* 
 
Asperthecin a b ti 
No compound 0.97 ± 0.01 4.7 ± 1.3 5.5 ± 1.5 
50 μM 0.79 ± 0.02** 5.0 ± 1.3 5.9 ± 0.9 




a b ti 
 
No compound 0.96 ± 0.02 4.1 ± 0.8 4.7 ± 1.0 
50 μM 0.85 ± 0.01*** 5.0 ± 0.8 5.8 ± 1.0 














Table 3.2 Three individual microtubule polymerization curves for each condition were fit to a  
nonlinear Gompertz growth function: 
y = ae –e [(t-ti)/b)] 
Where y is the amount of microtubule polymerization measured at time t, a is the maximum 
amount of microtubule polymerization observed, ti is the point of inflection of the curve, and b is 
inversely proportional to the apparent rate of polymerization. The average values for the 
parameters a, b, and ti were determined and compared to the no-compound control using a one-
way analysis of variance followed by Dunnett’s multiple comparison test to determine statistical 














3.4.4 Effect on tau- microtubule intereactions. Tau’s normal function is to promote 
microtubule assembly and further stabilise the mcirotubule structure. We therefore sought to 
determine whether the most potent compounds, asperthecin, asperbenzaldehyde and 2,ω-
dihydroxyemodin, interfered with the normal function of tau. Microtubule polymerization was 
monitered using DAPI fluorescence in the presence of tau with or without the compound. 
Although, all three compounds showed a dose-dependent reduction in tau’s ability to polymerize 
microtubules, significant microtubule stabilization was retained at high concentrations of the 
inhibitors (Figure 3.6).  A statistical analysis of the effects of anti-tau aggregation compounds on 
the stabilization of microtubules is shown in Table 3.2. 
3.5 Discussion  
Tau aggregation is a common pathological condition seen in AD and other tauopathies. The 
location and amount of tau aggregation correlates well with the type and severity of the disease 
progression42. There is great interest in finding small molecules which can inhibit tau 
aggregation. Previous studies have identified several classes of compounds including 
anthraquinones, polyphenols and phenothiazines that show promise as aggregation inhibitors. 
These compounds have a common structural motif of ring structures, which are believed to 
interact with the β-sheet structure found at the core of the tau aggregates, therefore preventing 
further filament formation. There is a need for identifying additional lead anti-tau aggregation 
compounds for further development into therapeutics.  
Fungi have been long been a source for great medicinal products such as antibiotics220, and 
recent advances in genetic manipulation of secondary metabolite producing gene clusters have 
enhanced our capabilities to obtain, purify and characterize fungal natural products.  Dr. Berl 
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Oakley and his colleagues have identified many biosynthetic pathways in Aspergillus nidulans 
that produce of a wide variety of secondary metabolites including anthraquinones, xanthones and 
other metabolites in amounts that allow ready purification205, 221. Many of these small 
compounds have aromatic ring structures similar to those found in tau aggregation inhibitors.  
Out of the 17 compounds chosen, three compounds inhibited tau aggregation and gave us 
reproducible and consistent results. Three compounds out of 17 is a good number of hits for a 
preliminary screen, therefore supporting our hypothesis for choosing compounds with ring 
structures. Among the hits, 2, ω-dihydroxyemodin and asperthecin belong to the anthraquinone 
class of compounds. Other anthraquinones have previously been identified as tau aggregation 
inhibitors, particularly emodin which we included in our study. Emodin was previously shown to 
be a strong inhibitor of tau polymerization with an IC50 value in the range of 1-5 µM166. In our 
assays, emodin was not a potent inhibitor and at the same time it was surprising to see our potent 
compounds having high IC50 values in the range of 40-200 µM. This difference in activity and 
IC50 values could be due to differences in the assay conditions. Compared to the previous emodin 
study, our assay conditions strongly drive aggregation and therefore may provide a more 
rigorous test for inhibition. The previous study was done using the glycosaminoglycan heparin 
sulfate as an inducer166 and previous studies have shown that arachidonic acid induces 
approximately three times the amount of aggregation as heparin sulfate under similar 
conditions218. The tau isoforms used in the previous study were the 0N3R and 0N4R isoforms 
which have been shown to be less prone to aggregation than the 2N4R isoform used in this 
study14. Therefore, these factors could provide an explanation for the higher IC50 values seen in 
our assays compared to those in the previous studies.  
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We have identified compounds belonging to the class of anthraquinones as tau aggregation 
inhibitors, while none of the xanthones were effective. Xanthones and anthraquinones both 
possess ring structures but there is a difference in the groups on their central ring. 
Anthraquinones contain 2 keto groups on their central ring, while xanthones have a single keto 
group and an ether linkage. The keto groups could therefore be playing an important role in 
inhibiting tau aggregation. The keto groups on the central ring could be better aligned to interact 
with the β-sheet forming sequences compared to the xanthone ring. It is interesting that 
arachidonic acid can adopt ring-like conformations when in solution and heparin sulfate also 
contains ring structures. Therefore, it is possible that the compounds bind to tau in a similar 
fashion as the inducer molecules but create a conformational change upon binding which blocks 
further binding to other tau molecules.   
Asperbenzaldehyde has a chemical structure that is different from all the previously identified 
tau aggregation inhibitors. It has a single aromatic ring and is a stable intermediate in the 
azaphilone biosynthetic pathway.  This molecule is particularly interesting because it can be 
modified in 2 -3 steps to form azaphilones. Azaphilones are a group of compounds which exhibit 
a great variety of biologically important activities including antioxidant and anti-inflammatory 
activities, which could be useful for therapeutics against AD222. Further, asperbenzaldehyde has 
weak lipoxygenase-1 (LOX-1) inhibitory activity which can be converted into a series of string 
LOX-1 inhibitors by simple modifications211. We know that fatty acid levels are elevated in 
AD223, therefore inhibition of LOX-1 would be useful and derivatives of Asperbenzaldehyde 
could therefore have dual therapeutic activity against AD.  
The most potent compounds partially preserve tau’s ability to bind to tubulin and promote 
microtubule assembly. They do not completely inhibit tau’s function of stabilizing the assembly 
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of tubulin into microtubules. It was not surprising that some diminution occurred in presence of 
these compounds because the sequences which are likely responsible for tau aggregation 
275VQIINK280 and 306VQIVYK311, reside in the microtubule binding repeats44, 202. Therefore, if 
the compounds are interacting with these motifs, they would have some impact on the 
microtubule stabilization as well. It is encouraging that these compounds retain some tau 
function and therefore are promising future seed compounds which could be used to develop 
better analogues/ derivatives with greater aggregation inhibiting ability and fewer effects on tau-
microtubule interactions.  
In this study we have therefore identified a novel aggregation inhibitor molecule, which is also 
an intermediate in an azaphilone synthesis pathway. It would be interesting to determine whether 
the azaphilones derived from asperbenzaldehyde retain this ability to inhibit aggregation. We 
have also shown that selected secondary metabolites from fungi include seed compounds which 









Chapter IV  Azaphilones as tau aggregation inibitors: Second generation compounds 
obtained from Aspergillus nidulans  
4.1 Introduction  
Tau aggregation is one of the hallmarks that define pathology in AD and other tauopathies224, 225. 
These tau aggregates appear in different forms in tauopathies including neurofibrillary tangles 
(NFTs) found in cell bodies and cortical deposits of dystrophic neurites and neuropil threads226. 
Tau aggregates serve as markers for differential diagnosis and disease staging55. Tau aggregates 
can promote disease propagation227 and also serve as a direct source of toxicity66, 228. Therefore, 
tau aggregation is a pathological process which is not related to normal functions of tau, and this 
makes it a good therapeutic target to apply diverse strategies for inhibiting misfolding and 
aggregation of tau and eventually halt or reverse disease progression229.  
Previously, we screened seventeen secondary metabolites obtained from Aspergillus nidulans 
which predominantly had fused ring structures and found three compounds that inhibited tau 
aggregation in a dose dependent fashion in vitro230. Among these compounds asperthecin and 2, 
ω – dihydroxyemodin belonged to the class of anthraquinones. This was not a surprising result 
because compounds belonging to this class have been identified as tau aggregation inhibitors 
(TAIs) in vitro166. A third compound, asperbenzaldehyde was the most interesting compound 
among these because it was a structurally novel tau aggregation inhibitor and it is a chemical 
precursor to a class of compounds called azaphilones.  
Azaphilones are an interesting class of compounds having a great variety of biologically 
important activities including antimicrobial activity, enzyme inhibition such as topoisomerase II 
inhibition, caspase 3 inhibition, and inhibition of gp120-CD4 binding among others (reviewed 
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in222 ). Several azaphilones are also known to exhibit lipoxygenase inhibitor activity,211 which 
could be useful in AD to reduce elevated fatty acid metabolite levels223. We therefore sought to 
determine whether azaphilones derived from asperbenzaldehyde possessed tau aggregation 
inhibition activity, hoping that they would prove to have two biological targets relevant to 
treating AD.  
Dr. Berl Oakley and his colleagues prepared a small library of azaphilones obtained from 
asperbenzaldehyde. We used standard biochemical assays to determine the ability of azaphilones 
to inhibit tau aggregation and its effect on tau’s ability to polymerize microtubules. We found 
that all azaphilones derived from asperbenzaldehyde inhibited tau aggregation assembly, while 
four compounds showed an additional ability to dissolve pre-formed tau aggregates. The most 
potent compounds retained the majority of tau’s microtubule stabilizing functions.  
4.2 Experimental procedures  
4.2.1 Compounds. The compounds were made by Dr. Berl Oakley’s lab members, Dr. Clay 
Wang’s lab members (University of Southern California) and Andrew Riley, Prizinsano Lab, 
KU. Asperbenzaldehyde was purified from A. nidulans and converted to the compounds aza-7–
aza-17  as described previously211 with the following minor modifications. The Oakley lab 
constructed a number of strains with various promoter combinations and used a variety of 
induction conditions to maximize asperbenzaldehyde production. The best yields were obtained 
with strain LO8355 (pyrG89, pyroA4, riboB2, nkuA::argB, stcJ::AfriboB, AN1029(p):: AfpyrG-
alcA(p), AN1033::AfpyroA, alcR(p)::ptrA-gpdA(p)). In this strain, the promoter of the 
asperfuranone biosynthesis transcription factor AN1029 (using the AspGD nomenclature; 
http://aspergillusgenomes.org/) is replaced with the highly inducible alcA promoter, and the alcR 
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promoter is replaced with the strong, constitutive gpdA promoter (−1241 to −1). AN1033 is 
replaced with the AfpyroA gene to interrupt the asperfuranone biosynthesis pathway, causing 
asperbenzaldehyde to accumulate. Growth was in lactose minimal medium (20 g/L lactose, 6 g/L 
NaNO3, 0.52 g/L KCl, O.52 g/L MgSO4·7H2O, 1.52 g/L KH2PO4, 1 mL/L trace elements 
solution)231. Spores were inoculated at 106/mL into 500 mL of medium in a 2 L flask. Incubation 
was at 37 °C on a gyratory shaker, and induction was with 30 mM methyl-ethyl-ketone, added 
55 h after inoculation. Cultures were harvested 6 days after inoculation. Yields of purified 
asperbenzaldehyde were greater than 2 g/L, representing an approximate conversion of 10% of 
the carbon source to final product. 
4.2.2 Protein preparation. Full-length 2N4R tau (441 amino acids) was expressed in 
Escherichia coli and purified as described previously194.  
4.2.3. Inhibition of Tau Aggregation. 75 μM arachidonic acid was used to initiate the 
aggregation of 2 μM tau in polymerization buffer (PB) (10 mM HEPES (pH 7.64), 5 mM DTT, 
100 mM NaCl, 0.1 mM EDTA, and 3.75% ethanol) as previously described218. Compounds 
dissolved in DMSO were added to a final concentration of 200 μM and incubated with tau 
protein in PB 20 min prior to the addition of arachidonic acid. The reactions were allowed to 
proceed for 16 h at room temperature before analysis230. For heparin-induced tau assembly 
inhibition reactions, 0.6 μM heparin was used to initiate aggregation of  2 μM tau in 
polymerization buffer for heparin (PBh) (10 mM HEPES (pH 7.64), 5 mM DTT, 17.7 mM NaCl) 
in vitro. Compounds dissolved in DMSO were added to a final concentration of 100 μM and 
incubated with tau protein in PB 20 min prior to the addition of heparin. The reactions were 




Figure 4.1  
 
Figure 4.1 Compounds used in this study. The core structure of the azaphilone compounds is 
shown with the positions of modifications indicated by R1, R2, and R3. Structures of the 11 
compounds used in this study: aza-7, aza-8, aza-9, aza-10, aza-11, aza-12, aza-13, aza-14, aza-
15, aza-16, and aza-17. 
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4.2.4. Disassembly of Preformed Filaments. Preformed tau filaments were generated with 2 
μM tau and 75 μM ARA in PB as described above for 6 h at room temperature. Compounds 
dissolved in DMSO were added to the tau solution at final concentrations indicated in the Results 
section and figure legends. The reactions were allowed to proceed at room temperature for 12 h 
before analysis. For heparin-induced tau aggregation assays, preformed tau filaments were 
generated with 2 μM tau and 0.6 μM heparin in PBh as described above for 12 h at 37 °C. 
Compounds dissolved in DMSO were added to the tau solution at final concentrations indicated 
in the Results section and figure legends. The reactions were allowed to proceed at 37 °C for 24 
h before analysis. 
4.2.5. Filter Trap Assay. The amount of tau aggregates following assembly or disassembly 
reactions was determined by filter trap assay as described previously230. Reactions were diluted 
into TBS such that they contained 20 ng of protein in 300 μL. For heparin-induced tau 
aggregation reactions, the reactions were diluted into TBS such that they contained 60 ng of 
protein in 300 μL. Solutions were passed through a nitrocellulose membrane using house 
vacuum in a dot-blot apparatus. The aggregates trapped on the membrane were detected by either 
general antibodies (a mixture of tau 5 antibody219 at 1:50 000 dilution, tau 12 antibody96 at 
1:250 000 dilution, and tau 7 antibody 192 at 1:250 000 dilution) or antibodies to toxic 
conformations (TNT1232 at 1:200 000 or TOC1233 at 1:7000). All antibodies were a kind gift 
from Drs. Nick Kanaan and Lester I. Binder. HRP-linked goat anti-mouse IgG (general 
antibodies and TNT1) or HRP-linked goat anti-mouse IgM (TOC1) (Thermo Scientific, 
Rockford, IL) were used as the secondary antibodies, and blots were developed using ECL 
(enhanced chemiluminescence) western blotting analysis system (GE Healthcare, 
Buckinghamshire, UK). Images were captured with a Kodak Image Station 4000R or ChemiDoc-
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It2 imager and were quantified using the histogram function of Adobe Photoshop 7.0. Statistical 
analyses were performed using unpaired t-tests to compare the triplicate values to control values. 
4.2.6 Transmission Electron Microscopy. Polymerization reaction samples were diluted 1:10 
in PB and fixed with 2% glutaraldehyde for 5 min. Fixed samples were placed on Formvar 
carbon-coated grids and stained with uranyl acetate as previously described230. Images were 
captured with a Technai F20 XT field emission transmission electron microscope (FEI Co., 
Hillsboro, OR) and Gatan Digital Micrograph imaging system (Gatan, Inc., Pleasanton, CA). The 
filaments were quantified using Image-Pro Plus 6.0 software (Media Cybernetics, Inc., 
Rockville, MD) as previously described230. For quantitative analysis, filament lengths were 
placed into bins as described in Results. Statistical analyses were performed using unpaired t-
tests to compare four or five replicates for each bin size with the no-compound data serving as 
reference values. 
4.2.7 Tubulin Polymerization Assay. Polymerization of tubulin was measured using a tubulin 
polymerization assay kit (BK006P, Cytoskeleton, Inc., Denver, CO) following the 
manufacturer’s protocol. Briefly, 2 mg/mL porcine tubulin was incubated with 1.5 μM tau and 
90 μM aza-8, aza-9, aza-12, or aza-13 compound. Tubulin polymerization was monitored by 
turbidity at 340 nm in a Varian 50 MPR microplate reader at 37 °C for 1 h. Experiments were 
performed in triplicate, averaged, and fit to a Gompertz growth equation as previously 
described14 using the equation  
y = ae –e [(t-ti)/b)] 
where y is the amount of microtubule polymerization measured at time t, a is the maximum 
amount of microtubule polymerization observed at an absorbance of 340 nm (max), ti is the point 
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of inflection of the curve at the time of maximum growth rate in minutes, and b is inversely 
proportional to the apparent rate of polymerization (kapp, min–1). The average values for 
parameters a, b, and ti were determined and compared to the no-compound control using a paired 
t-test to determine statistical significance. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001. 
4.3 Results 
4.3.1.  Tau aggregation inhibition assay  
Eleven compounds with the same azaphilone backbone differing at three points of diversity (R1, 
R2, and R3) were used in this study (Figure 4.1). Tau polymerization was initiated in vitro using 
a standard arachidonic acid induction assay218. The degree of tau aggregation inhibition for each 
compound was determined using a membrane filter assay234. This assay has been used previously 
to screen A. nidulans secondary metabolites including anthraquinones, xanthones, polyketides, a 
benzophenone, and the asperbenzaldehyde compound that was the parent compound for the 
synthesis of the azaphilones used in this study230. A mixture of antibodies to the amino terminal, 
central, and carboxy terminal regions of tau (tau 12, tau 5, and tau 7, respectively) was used to 
detect tau aggregates. In this assay, only compound aza-11 significantly reduced the amount of 
tau aggregation detected. Compounds aza-13 and aza-15 significantly increased the amount of 
tau aggregation, and the remaining compounds had no significant effect (Figure 4.2). 
4.3.2. The aggreates formed in the presence of the compounds were not toxic.  
Upon use of antibodies against toxic species of tau for detection, we observed that all 
azaphilones completely abolished recognition by the TOC1 antibody, which recognizes toxic 
oligomers in vitro and in Alzheimer’s disease tissue as compared to that for controls without 
compound (Figure 4.3 B). Similarly, significant reductions in recognition by TNT1, an antibody 
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that recognizes the phosphatase-activating domain of tau and is exposed in pathological forms of 
tau, were observed for all aza compounds as compared to that for controls without compound 
(Figure 4.3 A). 
4.3.3 All Azaphilones inhibited filament formation  
When the resulting tau aggregates from the inhibition reactions were visualized by electron 
microscopy, there were abundant numbers of long filaments in the absence of added compound 
(Figure 4.4). Surprisingly, all of the azaphilones inhibited the formation of long tau filaments 
that were observed in the absence of compounds. Instead, amorphous small aggregates were 
observed after treatment with the compounds (Figure 4.4). This degree of tau aggregation 
inhibition was similar to what was observed by electron microscopy for asperbenzaldehyde and 
asperthecin and was stronger than what was observed for 2, ω-dihydroxyemodin in Chapter 
III230. Because tau aggregation inhibitors that inhibit filament formation have previously been 
shown to stabilize off-pathway soluble oligomers that are large enough to be trapped in the 
membrane filter assay235, we believe that the mixture of tau antibodies to normal tau was 
detecting these aggregates in the filter trap assay (Figure 4.2). These aggregates do not seem to 
be toxic because of their lack of reactivity to TOC1 (Figure 4.3A) and TNT1 (Figure 4.3B). We 
did assays to detect whether the azaphilones block adherence of tau filaments to the EM grids 














































































Figure 4.2 Filter trap assay of tau filament formation. Tau polymerization reactions were 
performed with 2 μM tau and 75 μM arachidonic acid either with or without 200 μM compound. 
The compounds used are listed on the x axis. The resulting amount of tau filament formation was 
determined using a filter trap assay. The values for tau filament formation were normalized to the 
amount of aggregation in the absence of compound (dashed line). The amount of tau on the filter 
was detected using a mixture of antibodies tau 5, tau 7, and tau 12. Values are the average of 
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Figure 4.3 Filter trap assay of tau filament formation. Tau polymerization reactions in (A and 
B) were performed with 2 μM tau and 75 μM arachidonic acid either with or without 200 μM 
compound. The compounds used are listed on the x axis. The resulting amount of tau filament 
formation was determined using a filter trap assay. The values for tau filament formation were 
normalized to the amount of aggregation in the absence of compound (dashed line). Negative 
values indicate that there was less detectable tau on the filter after treatment with a compound 
than was observed with monomeric tau in the absence of arachidonic acid. The amount of tau on 
the filter was detected using (A) antibody TOC1 and (B) antibody TNT1. The observation 
suggests that the tau aggregates that are retained on the filters are not in the toxic oligomeric 
form recognized by the TOC1 antibody and that the phosphatase domain recognized by TNT1 
antibody is not exposed. Values are the average of three trials ± SD. *, P ≤ 0.05; **, P ≤ 0.01; 







Figure 4.4  
 
 
Figure 4.4 Electron microscopy of tau filament formation in the presence of azaphilone 
derivatives. Tau polymerization reactions were performed with 2 μM tau and 75 μM arachidonic 
acid either with or without 200 μM compound. Aliquots of the reactions were prepared for 
negative stain electron microscopy. Representative images are shown for no compound control, 
aza-7, aza-8, aza-9, aza-10, aza-11, aza-12, aza-13, aza-14, aza-15, aza-16, and aza-17. The scale 





4.3.4 Aza-8, aza-9, aza-12 and aza-13 completely disassembled pre-formed tau filaments. To 
determine whether these compounds can disassemble preformed tau aggregates, tau aggregation 
was allowed to proceed for 6 h before the addition of compounds to a final concentration of 200 
μM. After 12 h, the effect of compounds on the tau aggregation was examined by a filter trap 
assay using the mixture of antibodies against normal tau (Figure 4.5). All compounds reduced 
the amount of preformed tau filaments, with compounds aza-8, aza-9, aza-11, aza-12, and aza-13 
having the greatest activity. Electron microscopy was used to validate and extend the results 
from the filter trap assay. Compounds aza-8, aza-9, aza-12, and aza-13 substantially reduced the 
pre-existing filament mass, whereas the other compounds had less effect (Figure 4.6). To test 
whether compounds aza-8, aza-9, aza-12, and aza-13 were not simply blocking the adherence of 
tau filaments to the electron microscopy grids, compounds were added to preformed tau 
filaments and were immediately prepared for electron microscopy without allowing time for 
disassembly to occur. Under these conditions, none of the compounds blocked the binding of the 
filaments to the grid (figure 4.8). Quantitative analysis of the filament lengths in the presence 
and absence of compounds confirmed that compounds aza-8, aza-9, aza-12, and aza-13 had 
fewer aggregates overall compared to that in reactions without compound and virtually no 




















































































Tau 5 + tau  7 + tau 12
 
Figure 4.5 Filter trap assay of tau filament disassembly. Tau polymerization reactions were 
performed with 2 μM tau and 75 μM arachidonic acid at room temperature. After 6 h, 200 μM 
compound or an equal volume of DMSO was added to the reactions. The compounds used are 
listed on the x axis. The resulting amount of tau filament formation was determined using a filter 
trap assay. The values for tau filament formation were normalized to the amount of aggregates 
detected in the absence of compound (dashed line). Negative values indicate that there was less 
detectable tau on the filter after treatment with a compound than was observed with monomeric 
tau in the absence of arachidonic acid. The amount of tau on the filter was detected using a 
mixture of antibodies tau 5, tau 7, and tau 12. Values are the average of three trials ± SD. *, P ≤ 






Figure 4.6  
 
Figure 4.6 Electron microscopy of tau filament disassembly in the presence of azaphilone 
derivatives. Tau polymerization reactions were performed with 2 μM tau and 75 μM arachidonic 
acid at room temperature. After 6 h, 200 μM compound or equal volume of DMSO was added to 
the reactions. Aliquots of the reactions were prepared for negative stain electron microscopy. 
Representative images are shown for no compound control, aza-7, aza-8, aza-9, aza-10, aza-11, 
aza-12, aza-13, aza-14, aza-15, aza-16, and aza-17. The scale bar in the lower right panel 



























Figure 4.7 Filament length distributions. Tau disassembly reactions were performed and 
viewed by electron microscopy. The filaments remaining following incubation with or without 
compound were measured and placed into bins according to their length (30–50, 50–100, 100–
150, 150–200, and >200 nm). The lengths within a bin were summed to determine the total 
amount of filament length in each bin. (A) Length distributions for filaments in the control 
reaction without compound. The length distributions are also shown for filaments remaining 
following incubation in the presence of (B) aza-7, (C) aza-8, (D) aza-9, (E) aza-10, (F) aza-11, 
(G) aza-12, (H) aza-13, (I) aza-14, (J) aza-15, (K) aza-16, and (L) aza-17. Each point is the 




















Figure 4.8 Pre-formed tau filaments binding to electron microscopy grids in the presence of 
azaphilone compounds. To test whether azaphilone compounds may block adherence of tau 
filaments to EM grids, preformed tau filaments were mixed with compounds aza-8, aza-9, aza-
12, and aza-13 and immediately prepared for electron microscopy without allowing time for 
disassembly. As seen in the micrographs, similar amounts of filaments were observed with or 
without the added azaphilone compounds, indicating that the compounds do not block adherence 









4.3.5 Aza-8, aza-9, aza-12 and aza-13 disassembled filaments in a dose-dependent fashion. 
The IC50 of the four most potent compounds was determined using the filter trap assay. The 
amount of preformed filaments remaining following treatment with compounds for 12 h was 
reduced in a concentration-dependent manner for all four compounds tested (Figure 4.9). 
Compound aza-9 had an IC50 of 56 ± 14 μM, compared to 118 ± 19, 98 ± 16, and 216 ± 18 μM 
for compounds aza-8, aza-12, and aza-13 respectively, indicating that aza-9 has the most activity 
for dissolving preformed tau filaments in vitro (Figure 4.9). 
4.3.6 Aza-9 disassembled heparin-induced tau filaments. In a number of studies, heparin has 
been used to induce tau aggregation. Because heparin-induced tau filaments might be different 
from arachidonic acid induced filaments, we wished to determine if aza-9 inhibited heparin-
induced tau aggregation or disassembled heparin-assembled tau aggregates. We chose aza-9 
because it was the most potent compound among the 11 azaphilones. Filter trap assays were 
performed using the mixture of antibodies against normal tau, the TOC1 antibody, and the TNT1 
antibody. Aza-9 significantly reduced the assembly of TOC1- and TNT1-positive aggregates 
(Figure 4.10A). The addition of aza-9 also resulted in the significant disassembly of preformed 








Figure 4.9  





IC50 = 118.47  19.33 M
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Figure 4.9 IC50 determination tau filament disassembly. Polymerization reactions at 2 μM 
tau and 75 μM arachidonic acid were performed at room temperature. After 6 h, compounds 
were added to these reactions at several different concentrations, and the mixtures were 
incubated for an additional 12 h. The resulting amount of tau filaments in the reaction was 
determined by a filter trap assay detected by a mixture of antibodies to normal tau (tau 5, tau 7, 
and tau 12). The amount of polymerization was normalized to controls in the absence of 
compound (100%). The normalized data was plotted against the log of the inhibition 
concentration and fit to a dose–response curve to determine the IC50 for (A) Aza-8, (B) Aza-9, 
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Filter trap assay for filament assembly and disassembly of heparin-induced tau filaments. 
(A) For assembly inhibition, 100 μM aza-9 was incubated with 2 μM tau for 20 min before the 
addition 0.6 μM heparin. Sixteen hours after induction, the degree of aggregation was 
determined using the filter trap assay detected by a mixture of antibodies to normal tau (tau 5, tau 
7, and tau 12), an antibody to oligomeric tau (TOC1), and an antibody to a toxic conformation of 
tau (TNT1). The average of three independent trials ± SD is shown for no compound controls 
(white bars) and 100 μM aza-9 (black bars). (B) 2 μM tau and 0.6 μM heparin were incubated 
together for 12 h prior to the addition of 100 μM aza-9 or an equal volume of DMSO. 
Disassembly reactions proceeded for an additional 24 h, and the degree of aggregation was 
determined using the filter trap assay detected by a mixture of antibodies (tau 5, tau 7, and tau 
12), TOC1, and TNT1. The average of three independent trials ± SD is shown for no compound 








4.3.7 Aza-8, aza-9, aza-12 and aza-13 did not completely inhibit tau’s ability to polymerize 
microtubules. We chose the most potent azaphilone derivatives, aza-8, aza-9, aza-12, and aza-
13, to determine their effects on the normal function of tau to stabilize microtubules. Tubulin 
was mixed with tau in the presence or absence of 90 μM compound, and the resulting 
microtubule formation was monitored by turbidity. All polymerization curves were fit using a 
Gompertz growth equation (Figure 4.11). While all four compounds affected the apparent rate 
and maximum amount of microtubule formation at the concentration tested (Table 4.1), tau still 
retained a significant ability to stabilize microtubule formation. 
4.4 Discussion  
Tau-based therapeutic strategies have recently been gaining additional attention largely due to 
the major role that tau pathology plays in many neurological disorders including Alzheimer’s 
disease. Several tau-directed therapeutic strategies with disease-modifying potential have been 
identified, including modulating tau phosphorylation, microtubule stabilization, tau aggregation 
inhibitors, and tau clearance using antibodies236-241. Conversion of soluble monomeric tau into 
insoluble tau aggregates could, potentially, result in both loss-of-function and gain-of-function 
toxicities40. Therefore, inhibiting aggregation of tau might prevent formation of the toxic 
oligomers or tangles. Inhibiting aggregation could also increase the levels of monomeric tau, 
thereby increasing the chances for its clearance through chaperone-mediated processes. Previous 
studies have identified several tau aggregation inhibitor (TAI) molecules, including those 
belonging to the class of anthraquinones, phenothiazines, and a benzothiazolidine derivative, 
among others166, 242, 243. One TAI, a stable, reduced form of methylthioninium chloride, is 
currently in Phase III clinical trials160, indicating that this approach has promise and that it is, 
consequently, worthwhile to identify additional structural backbones with this activity. 
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Figure 4.11 Microtubule assembly in the presence of the most potent azaphilone tau 
aggregation inhibitors. Tubulin was incubated with either tau protein alone or tau in the 
presence of (A) aza-8, (B) aza-9, (C) aza-12, or (D) aza-13 at a concentration of 90 μM. 
Microtubule assembly was monitored by absorbance at 340 nm (y axis) over time (x axis). Each 
point is the average of three independent trails ± SD. All data were fit to Gompertz growth curve 
(dashed and solid lines for no compound and 90 μM azaphilones, respectively). For clarity, only 














Table 4.1. Statistical analysis of the effects of compounds aza-8, aza-9, aza-12, and aza-13 
on the stabilization of microtubules. 
  ti (min) kapp (min
-1) Max (A340) 
Aza-8 
- 3.08   ± 1.28 0.87 ± 0.14 0.76  ± 0.36 
+ 13.42 ± 6.59 0.12 ± 0.02*** 0.36 ± 0.14* 
     
Aza-9 
- 2.26 ± 0.65 0.62 ± 0.08 0.65 ± 0.38 
+ 5.03 ± 1.93 0.26 ± 0.19* 0.38 ± 0.10* 
     
Aza-12 
- 3.11 ± 1.22 0.78 ± 0.09 0.75 ± 0.10 
+ 12.83  ± 1.35*** 0.09 ± 0.02*** 0.50 ± 0.04* 
     
Aza-13 
- 2.58 ± 1.29 0.86 ± 0.17 0.72  ± 0.06 
+ 15.65 ± 7.72* 0.12 ± 0.05** 0.30  ± 0.07** 
 
Table 4.1. Statistical analysis of the effects of compounds aza-8, aza-9, aza-12, and aza-13 
on the stabilization of microtubules. Max (A340) is the maximum amount of microtubule 
polymerization, ti is the point of inflection of the curve at the time of maximum growth rate in 
minutes, and b is inversely proportional to the apparent rate of polymerization (kapp, min
–1), as 
determined from the fit of three individual microtubule polymerization curves for each condition 










Many of the previously identified TAIs are composed of fused ring structures believed to be 
capable of interacting with the β-sheet structures formed in tau aggregates, thereby inhibiting 
formation of tau filaments230, 235  
Fungal extracts are known to include pharmaceutically important secondary metabolites220. We 
therefore previously screened 17 secondary metabolites obtained from the fungus A. nidulans for 
TAIs due to their structural similarity to previously identified TAIs230. From this screen, we 
identified three compounds that inhibited tau aggregation at micromolar concentrations. Two of 
these compounds belong to the anthraquinone class of compounds, and one was structurally 
unique from all previously identified TAIs. We were particularly interested in this compound, 
asperbenzaldehyde. Asperbenzaldehyde is a precursor to an important class of natural products 
called azaphilones. Azaphilones are a structurally diverse group of polyketides that share a 
highly oxygenated bicyclic core and chiral quaternary center222. The azaphilones used in this 
study were obtained by semisynthetic diversification of asperbenzaldehyde. 
All 11 azaphilones inhibited the formation of tau filaments, but some of them produced small 
amorphous tau aggregates, which can be seen in the electron micrographs in Figure 4.4. These 
aggregates were not recognized by TOC1232 and TNT1233 antibodies, which bind to toxic forms 
of tau; therefore, we believe that these compounds promote the formation of small off-pathway 
aggregates of tau that are not toxic and do not act as seeds for further tau filament assembly. The 
induction of these aggregates could be similar to soluble aggregates of tau induced by porphyrin 




From a therapeutic point of view, TAIs would be more useful if they could also dissolve 
preformed tau filaments because they could theoretically be beneficial to patients that already 
demonstrate cognitive impairments. We found that a subset of the compounds, aza-8, aza-9, aza-
12, and aza-13, showed this property. These four compounds have Br or Cl at position R1, 
whereas the other compounds have either I or H at R1 (Figure 4.1). Therefore, halogenation at 
position R1 may not necessarily be important for inhibition of tau filament formation, but 
electron-withdrawing groups at R1 specifically seem to enhance disassembly of tau filaments. Cl 
and Br are more electronegative (3.0 and 2.8, respectively) than I (2.5) and H (2.1), indicating 
that increased electronegativity at position R1 could have a significant impact on the activity of 
tau aggregation inhibitors with this scaffold. The four disassembly causing compounds have a 
ketone at position R3, whereas the presence of the CHCO2Et moiety at the same position seems 
to virtually eliminate disassembly, even with halogenation. The impact of the chemical groups at 
the R2 position seems to be dependent upon the substitution at R1. Compounds aza-8 and aza-12 
both have Cl at R1, but they possess acetate and hydroxyl groups at R2, respectively. Despite 
this structural difference, there is no significant difference in their activity levels. However, 
compounds aza-9 and aza-13, both containing Br at R1 and acetate and hydroxyl groups at R2, 
respectively, differ in their levels of activity. Aza-9 is more potent than aza-13; therefore, 
positioning of the acetate group at R2 in the presence of a Br at R1 might be important for 
compound activity. 
Additionally, all four disassembly causing compounds have lipoxygenase-1 inhibitory activity in 
the low micromolar range (IC50 of 2–8 μm)
211. Inhibition of LOX-1 may help to reduce fatty acid 
metabolites of arachidonic acid and docosahexaenoic acid that are elevated in Alzheimer’s 
disease223. These compounds could therefore have two positive therapeutic activities in tau 
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dementias. The relatively high IC50 values of our compounds indicate that they are unlikely to be 
of therapeutic value, and we do not know if they have suitable bioavailability or pharmacokinetic 
properties. It is important, however, to identify new scaffolds with the appropriate biological 
activity for further development. We believe that these compounds provide a novel TAI scaffold 
with the added features that they inhibit LOX-1 and some of them disassemble preformed tau 
aggregates. 
The core of tau aggregates is made up of highly ordered β-sheet structures202. The tau protein has 
two hexapeptide motifs 275VQIINK280 and 306VQIVYK311 that are absolutely essential for the 
formation of tau aggregates44. Compounds that inhibit tau aggregation could, therefore, be 
interacting with these hexapeptide motifs. Azaphilones can react with primary amines to form 
vinylogous γ-pyridines222. It is therefore possible that these azaphilones could covalently bind to 
the primary amine of lysine in the hexapeptide motifs. The hexapeptide motifs lie within the 
microtubule-binding repeat (MTBR) region of tau protein, raising the possibility that compounds 
that inhibit tau aggregation would inhibit tau’s ability to bind to tubulin and promote its 
assembly into microtubules. Even at relatively high concentrations of the group of compounds 
that disassemble preformed aggregates, tau’s natural function was not completely inhibited. 
However there are two obvious explanations 1) azaphilones are not binding to the hexapeptide 
repeats, and are exerting their activities in some other way or 2) azaphilones bind to the repeats 
but only partially inhibit the tau-tubulin interaction. In this regard we note that 275VQIINK280 and 
306VQIVYK311 are located in the inter-repeat region and not directly within the 18-amino acid 
imperfect repeat regions of the MTBR 
In conclusion, this study shows that these compounds inhibit assembly of tau aggregates, 
disassemble preformed tau aggregates, and partially preserve tau’s ability to bind to tubulin and 
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promote microtubule assembly. These compounds provide a promising novel scaffold for TAI 
molecules. The structure–activity relationship studies give us several leads for the probable 
important chemical groups required in this scaffold structure required for the anti-tau aggregation 
activity of the compounds. Further studies on the interaction between the compounds and tau 

















Chapter V:  Using NMR to determine interaction between Aza-9 and tau protein.  
5.1 Introduction  
Alzheimer’s disease is characterized by presence of intracellular abnormal tau aggregates and 
extracellular amyloid plaques. Tau aggregation occurs in many other diseases such as 
Frontotemporal dementia, Pick’s disease and other tauopathies. The primary initiation factor for 
the process of tau aggregation is not known as yet, though it is now agreed upon that tau 
aggregation plays a major role in disease pathogenesis. Therefore, inhibition of tau aggregation 
is a good therapeutic strategy which could potentially stop or reverse disease progression. There 
is a strong interest in identifying small molecules which could inhibit tau aggregation. Similar 
searches are also being done to find inhibitors for other aggregating proteins in other diseases 
such as α-synuclein in Parkinson’s disease, prion protein in Creutzfeldt- Jacob disease and 
transthyretin in systemic amyloidosis244, 245.  
In the search of tau aggregation inhibitors, we tested secondary metabolites obtained from 
Aspergillus nidulans for their ability to inhibit tau aggregation. In this screen, we identified a 
novel class of compounds, azaphilones as molecules which could inhibit tau aggregation in vitro 
as well as dissolve pre-formed tau aggregates without inhibiting the tau-microtubule interactions 
completely246. Among these, Aza-9 was the most potent compound. Aza-9 inhibited tau 
aggregation assembly and disassembled pre-formed tau aggregates with an IC50 value of 56 µM.  
















Figure 5.1 Hexapeptide motifs on full length tau protein. This cartoon depicts the protein 
structure of full length tau. Two exons E2 and E3 are seen at the N-terminal. There are four 
microtubule binding repeats (MTBR) at the C –terminal marked as R1 through R4. Exon E10 
codes for R2. The two hexapeptide motifs are located within the MTBR region shown in red 
blocks before the R2 and R3 regions. The first hexapeptide motif called PHF6 is 275VQIINK280 










Tau protein has two hexapeptide motifs which are found in the MTBR region near the C-
terminal of tau protein that are essential for tau aggregation. The tau molecules bind to each 
other via these hexapeptide motif regions to form β-sheet structures45. Aza-9 could therefore be 
interacting with residues in and around these motifs. The hexapeptide motif regions are 
275VQIINK280 which is referred to as PHF6 motif, and the 306VQIVYK311 which is referred to as 
PHF6* motif (Figure 5.1). Aza-9 affects the MT polymerization in the presence of tau. That 
further supports the hypothesis that tau could be interacting with the region in and around the 
hexapeptide motifs, because the motifs are located within the MTBR region.  
The aim of this study was to determine whether aza-9 interacts with tau and, to identify the 
potential residues in tau which could be involved in the interaction. We therefore did titration 
NMR experiments with tau and aza-9 and found that aza-9 interacts with specific residues in tau. 
We used different labeling techniques to obtain more information regarding the interaction.  
5.2 Experimental procedures  
5.2.1 Mutagenesis and Protein purification. Wild type tau and I308L mutant tau were cloned 
into PT7c vectors with an N-terminal polyhistidine tag as previously described 247 . The 
mutagenesis for I308L was done using the Quikchange site-directed mutagenesis kit from 
Stratagene (La Jolla, CA). The vector containing cells were grown in Minimal Media (Na2HPO4, 
KH2PO4 and NaCl). The minimal media was supplemented with 0.1M CaCl2, 1M MgSO4, 40% 
Glucose, Vitamin mix, Trace metal mix and Kanamycin. For obtaining 15N labelled tau, we 
added 15N NH4Cl to the minimal media. For obtaining ILV labeled tau, we supplemented the 
minimal media with Ile, Val and Leu during the log phase of growth of the culture, which is 
when the OD reaches 0.5 (before the IPTG induction step).  The proteins were isolated by 
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affinity chromatography through a Ni NTA Agarose (Qiagen, Valencia, CA) column followed by 
gel filtration through a Superdex 200 column on AKTA fast protein liquid chromatography 
(FPLC) (Amersham Biosciences, Piscataway, NJ) as described previously194. 
5.2.2. Preparing samples for NMR. The proteins were dialyzed into phosphate buffer (10mM 
Na2HPO4) using dialysis cassettes (Pierce, Rockford, IL) having a molecular weight cut-off of 
10KDa. The protein concentration used in all the experiments was 0.1 mM. Aza-9 was used in 
final concentrations of 0.1 mM, 0.2mM and 0.4 mM for titration studies against wild type tau 
and I308L mutant tau. The compounds were dissolved in DMSO. The total amount of DMSO in 
every NMR tube sample was less than 2%.  
5.2.3 Obtaining NMR spectra. We obtained 2-D 1H-15N HSQC NMR spectra for obtaining the 
full length tau spectrum and the titration experiments with wild type tau and aza-9. We also 
obtained 2-D NMR 1H-13C HSQC spectrum for ILV labelled tau and for titration studies with 
ILV labelled tau and Aza-9. These experiments were carried out under the guidance of Dr, 
Asokan at the KU NMR core facility. Kawaljit Kaur from the De Guzman lab helped in 
analyzing the data.  









5.3 Results:  
5.3.1 Obtained 2D spectrum of full length tau protein.  
    We labelled full length WT tau protein amide backbone with 15N and obtained a 1H-15N 
HSQC spectrum for the same. Tau is a natively unfolded protein and therefore the individual 
residue peaks were of overlapping nature rather than being very spread out as would be the case 
with structured proteins. There were certain residues which could be identified as individual 
peaks (Figure 5.2). 
5.3.2 Titration studies with Tau and Aza 9 
    We sought to determine whether aza-9 interacted with tau residues. We therefore did titration 
studies with increasing concentrations of aza-9 against tau. The protein concentration used was 
0.1mM throughout. Aza-9 was added in increasing ratios with WT tau in three separate 
experiments (WT: aza-9 in 1:0, 1:1, 1:2 and 1:4). With an increase in compound concentration 
11 specific residues of tau were affected as seen in figure 5.3. Out of the 11 residues, 7 peaks 
showed a reduction in peak intensity with an increase in Aza-9 concentration. These have been 
marked as circles in figure 5.4. 3 peaks showed subtle chemical deviations marked in squares in 
figure 5.4. These changes in the peaks are indicative of an intermediate exchange regime. This 
means that the compound interacts with the residues in micro molar range. This correlates with 
the IC50 value we obtained for disassembly which was around 56 µM. None of the other peaks 
showed any change in position or intensity in the presence of the compound. This means that 









Figure 5.2 2D 1H-15N HSQC NMR spectrum for full length 15N labelled tau protein. The X-












Figure 5.3 2D 1H-15N HSQC NMR spectrum for titration studies with 15N labelled Tau and 
Aza-9. The figure shows four overlaid 2D 1H-15N HSQC NMR spectra with increasing amounts 
of aza-9. The ratio of WT tau: aza-9 is denoted next to every spectrum description. The X-axis 







WT tau: Aza-9  
1:0 – Black  
1:1 – Red  
1:2 – Green  






Figure 5.4 2D 1H-15N HSQC NMR spectrum for titration studies with 15N labelled Tau and 
Aza 9. This figure is a zoomed in image of the spectrum in figure 5.3. The peaks marked with a 
red asterisk are the peaks showing a decrease in peak intensity with subtle chemical deviation 
with an increase in aza-9. The changes in peaks indicate an intermediate exchange regime in 





WT tau: Aza-9  
1:0 – Black  
1:1 – Red  
1:2 – Green  
1:4 – Blue  
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5.3.3 Titration studies with ILV labelled tau and aza-9 
    As mentioned in the introduction, we believe that aza-9 could be interacting with residues 
in/or around the hexapeptide motifs in the MTBR region. These motifs have lot of hydrophobic 
residues specifically Ile, Leu and Val. We therefore labelled these three amino acids specifically 
to determine whether aza-9 interacts with these residues. This would provide us more 
information regarding the residues involved in the interaction. We first obtained ILV-labelled tau 
1H-13C HSQC spectrum shown in figure 5.5. We further did titration studies with increasing 
concentrations of aza-9 against tau protein. The protein concentration used was 0.1mM 
throughout. Aza-9 was added in increasing ratios with ILV WT tau in three separate experiments 
(tau:aza9 in 1:0, 1:1, 1:2 and 1:4). As can be seen in the NMR spectrum for ILV labelled tau, the 
residues have overlapping peaks and therefore it was difficult to identify specific peaks affected 
after titration studies. One isolated Isoleucine peak showed a decrease in intensity with increase 
in aza-9 concentration (encircled in figure 5.6). Other affected peaks were buried among other 
closely located peaks and therefore were difficult to interpret. From this experiment, we 
understood that a one specific isoleucine is definitely affected by aza-9. But because of the 
overlapping nature of the other isoleucine peaks, it is difficult to interpret whether any other 









Figure 5.5 2D NMR 1H-13C HSQC spectrum for full length ILV- labelled tau protein 
In this spectrum the positions of the isoleucine residues are labeled, while the valine and leucine 














Figure5.6: 2-D NMR 1H-13C HSQC spectrum for titration studies with ILV labelled tau 
and Aza 9   
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5.4.4 Hexapeptide PHF6* is involved in interaction with aza-9 
        We sought to determine whether the isoleucine interacting with aza-9 is within the 
hexapeptide motif. We therefore created a tau construct with mutated PH6* motif I308L mutant. 
We chose the isoleucine from 306VQIVYK311 to mutate because it was more prone to making the 
β-sheet structure due to its alternating pattern of polar and nonpolar residues compared to that of 
275VQIINK280. We made a double labelled protein with 15N as well as Ile-labelled- 15N Ile I308L. 
We first obtained 2D Ile 1H-13C HSQC NMR Spectrum for 15N Ile I308L. Upon overlapping the 
Ile-spectra of WT tau with that of I308L, there was no change observed in the isolated isoleucine 
peak (Figure 5.7). Therefore, the affected isoleucine residue is not at 308 position. We would 
need to do more such single a.a. substitutions to assign the peaks in the future.  
        We further obtained a 2D NMR spectrum of 15N I308L (figure 5.8). The single a.a. 
substitution affected specific residues. Three individual peaks disappeared (encircled in figure 
5.9) from the I308L protein spectrum while several others showed minor changes. The three 
peaks seen (figures 5.3 and 5.4) clearly in WT tau were also involved in interaction with aza-9 as 
seen in the titration experiment. Therefore, based on this experiment we could say that aza-9 













Figure 5.7: 2-D NMR 1H-13C HSQC spectrum of isoleucine-labelled I308L protein. The 
NMR spectrum of wild type tau is in black. The NMR spectrum of I308L is in red and has been 













Figure 5.8: 2-D NMR 1H-13C HSQC spectrum of 15N-labelled I308L protein overlaid on the 
NMR spectrum of full length wild-type 15N-labelled tau protein. The NMR spectrum of wild 
type tau is in black. The NMR spectrum of I308L is in red and has been overlaid on the wild type 














Figure 5.9: Zoomed in 2-D NMR 15N-labelled I308L protein overlaid on 2-D NMR of full 
length wild-type 15N-labelled TAU protein. This image is a zoomed in image of the spectrum 
in figure 5.8. The NMR spectrum of wild type tau is in black. The NMR spectrum of I308L is in 
red and has been overlaid on the wild type tau spectrum. The encircled peaks denote peaks which 












This study gave us the following information regarding the mode of action of Aza 9 – 1) there is 
specific dose- dependent interaction between aza 9 and eleven tau residues. The nature of the 
interaction is that of intermediate exchange (micro molar range). 2) The hexapeptide motif 
residues are involved in this interaction. We do not eliminate the possibility of additional 
residues being affected that may not be visible in the 2D spectrum due to the overlapping nature 
of the peaks. 
The 15N labelling technique of tau gave us a 2D spectrum with closely placed peaks compared to 
that of ILV-specific labelling. The affected residues in the 15N labelled spectrum were easily 
distinguishable because they were relatively isolated peaks compared to the ILV spectrum we 
obtained for tau. The ILV-labeled 2D NMR spectra for tau had many overlapping peaks and 
made it difficult to identify individual residues. For example, tau has a total of 15 isoleucine 
residues in its a.a. sequence. In the spectrum, only one isoleucine peak was isolated while all the 
other 14 isoleucine residues had overlapping peaks making it difficult to identify the 14 residues. 
Titration studies with aza-9 and ILV-labelled tau showed reduction in peak intensity in that 
isolated isoleucine residue. There may be other isoleucine, valine or leucine residues affected but 
it we could not detect those because of the overlapping nature of the peaks. Upon replacing I308 
with leucine, we did not see a change in the isoleucine labelled tau spectrum. We now know that 
the affected isoleucine peak is not in the VQIVYK sequence. To identify this peak, we would 
have to replace other possible isoleucine residues and look for changes in this spectrum. There 
are two more isoleucine residues within the hexapeptide motifs. We would like to create more 
mutants with single isoleucine residues being replaced by leucine starting with I277L and I278L. 
This would help in identifying the affected isoleucine residue. The other strategy to assign the 
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peaks is by a special labelling technique, 15N amino acid specific labelling. Using this technique, 
we can label the amide backbone of specific amino acids, for example we can obtain a 15N 
Isoleucine spectrum. We would then get a spectrum showing 15 specific isoleucine peaks. These 
would be more spread out like in the 15N 2D spectrum, and therefore we can conduct titration 
experiments with aza-9 and potentially identify the number of specific isoleucine residues being 
affected. Further we can do specific mutations such as I308L, I277L and I278L to identify the 
peaks on the spectrum. We can this way obtain 15N Valine spectrum as well.   
Further studies need to be done to obtain more information about aza-9 – tau interaction. Firstly, 
we need to assign peaks for the MTBR region of tau protein. This will help us in identifying the 
residues affected. Aza-9 belongs to the class of azaphilones, which can react with primary 
amines to form vinylogous γ-pyridines222. It is therefore possible that these aza-9 could 
covalently bind to the primary amine of lysine in the hexapeptide motifs. It would be interesting 









Chapter VI Aza 9 is effective against aggregation enhancing truncation mutant 1-391  
6.1 Introduction 
Tau plays a prominent role in microtubule polymerization in neurons, axonal transport via 
microtubules and in neurite outgrowth among other functions. Tau is soluble, highly dynamic 
and is known to adopt a global hairpin folding structure when in solution5,248. Based on 
experiments done using electron microscopy, X-ray diffraction, FTIR, CD, fluorescence 
microscopy and NMR spectroscopy, tau behaves as a random coil in solution23, 44, 107. In spite of 
its hydrophilic character, tau aggregates to form insoluble tau filaments in Alzheimer’s disease 
and other tauopathies25, 201. In a diseased state, tau assumes specific conformations such as Alz50 
and Tau 66, which stabilize the tau structure and make it more prone to aggregation compared to 
normal tau92. Tau aggregation is known to play a major role in tau pathogenesis. The amount and 
location of tau tangles in the brain correlates well with disease progression42 and tau aggregates 
are known to induce toxicity in cell culture and animal models43.   
Tau undergoes many post-translational modifications such as phosphorylation, ubiquitination, 
acetylation and truncations which could be responsible for the conversion of soluble tau into 
insoluble tau aggregates. Truncation of tau protein occurs in AD and tau is known to be 
truncated at both its termini during disease progression. We have shown in our previous studies 
(unpublished, chapter II), that tau truncations have differential effects on tau aggregation 
mechanisms. We found that truncating tau at E391 at the C-terminal increases the amount and 





Figure 6.1  








Figure 6.1 Structure of the tau truncation mutant and the aza-9 compounds structure. A) 
The structures of the full length tau and that of the 1-391 truncation are shown. The N and the C 
termini have been labelled accordingly. N1 and N2 are the exons at the N –terminal of tau and 
the R1-R4 are the microtubule binding repeats shown near the C-terminal end. B) The structure 







Inhibiting tau aggregation is a good target for therapeutics against AD and other tauopathies, as 
they could help stop or reverse disease progression. There is a great deal of interest in finding 
compounds which can inhibit tau aggregation and/or disassemble tau aggregates. Compounds 
belonging to different classes including phenothiazines162, anthraquinones166, benzothioles175 and 
rhodanine-based compounds168 have been identified as tau aggregation inhibitors. We recently 
identified a novel class of compound, azaphilones as tau aggregation inhibitors246. In our study, 
we found that four azaphilones could inhibit tau filament assembly and could disassemble 
preformed tau filaments. Aza-9 among these was the most potent compound with an IC50 value 
of around 56 µM for disassembly against tau aggregates containing full length tau.  
Tau aggregates obtained from an AD brain are known to be reactive against antibodies such as 
MN423 and DC11, identify truncated tau95. Therefore from a therapeutic point of view, it would 
be useful to have tau aggregation inhibitors which can disassemble aggregates composed of 
truncated tau as well. In this study, we sought to determine whether our most potent azaphilone, 
aza-9 was effective against aggregates composed of 1-391. We did experiments to determine 
whether aza-9 can inhibit 1-391 filament assembly process and also disassemble pre-formed 1-
391 tau aggregates. Aza-9 inhibited 1-391 assembly and further disassembled 1-391 aggregates 
in a dose- dependent manner. 
6.2 Experimental procedures  
6.2.1 Protein expression and purification.  All wild-type (WT) and truncation constructs were 
expressed and purified as described previously194. The mutagenesis was done using the 
Quikchange site-directed mutagenesis kit from Stratagene (La Jolla, CA). The 1-391 truncation 
mutant was generated in a full-length 2N4R tau background contained in a pT7C vector. 
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6.2.2. Inhibition of Tau Aggregation. 75 μM arachidonic acid was used to initiate the 
aggregation of 2 μM tau in polymerization buffer (PB, 10 mM HEPES (pH 7.64), 5 mM DTT, 
100 mM NaCl, 0.1 mM EDTA, and 3.75% ethanol) in vitro as previously described218. 
Compounds dissolved in DMSO were added to a final concentration of 200 μM and incubated 
with tau protein in PB 20 min prior to the addition of arachidonic acid. The reactions were 
allowed to proceed for 16 h at room temperature before analysis.  
6.2.3 Disassembly of Preformed Filaments. Preformed tau filaments were generated with 2 μM 
tau and 75 μM ARA in PB as described above for 6 h at room temperature. Compounds 
dissolved in DMSO were added to the tau solution at final concentrations indicated in the Results 
section and figure legends. The reactions were allowed to proceed at room temperature for 12 h 
before analysis. 
6.2.4. Filter Trap Assay. The amount of tau aggregates following assembly or disassembly 
reactions was determined by filter trap assay as described previously230. Reactions were diluted 
into TBS such that they contained 20 ng of protein in 300 μL. Solutions were passed through a 
nitrocellulose membrane using house vacuum in a dot-blot apparatus. The aggregates trapped on 
the membrane were detected by general antibodies (a mixture of tau 5219 at 1:50 000 dilution, tau 
1296 at 1:250 000 dilution, and tau 7192 at 1:250 000 dilution). All antibodies were a kind gift 
from Drs. Nick Kanaan and Lester I. Binder. HRP-linked goat anti-mouse IgG  (Thermo 
Scientific, Rockford, IL) was used as the secondary antibody, and blots were developed using 
ECL (enhanced chemiluminescence) western blotting analysis system (GE Healthcare, 
Buckinghamshire, UK). Images were captured with a Kodak Image Station 4000R or ChemiDoc-
It2 imager and were quantified using the histogram function of Adobe Photoshop 7.0. Statistical 
analyses were performed using unpaired t-tests to compare the triplicate values to control values. 
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6.2.5. Transmission Electron Microscopy. Polymerization reaction samples were diluted 1:10 
in PB and fixed with 2% glutaraldehyde for 5 min. Fixed samples were placed on Formvar 
carbon-coated grids and stained with uranyl acetate as previously described230. Images were 
captured with a Technai F20 XT field emission transmission electron microscope (FEI Co., 
Hillsboro, OR) and Gatan Digital Micrograph imaging system (Gatan, Inc., Pleasanton, CA). The 
filaments were quantified using Image-Pro Plus 6.0 software (Media Cybernetics, Inc., 
Rockville, MD) as previously described230. Statistical analyses were performed using unpaired t-
tests to compare four or five replicates for each bin size with the no-compound data serving as 
reference values. 
6.3 Results 
6.3.1. Tau aggregation inhibition assay  
 1-391 polymerization was initiated in vitro using a standard arachidonic acid induction 
assay218.To determine whether aza-9 could inhibit assembly of tau filaments, it was added at a 
final concentration of 200 μM, was preincubated with 2 μM tau for 20 min before the addition of 
75 μM arachidonic acid. The degree of tau aggregation inhibition was determined using a 
membrane filter assay234. A mixture of antibodies to the amino terminal, central, and carboxy 
terminal regions of tau (tau 12, tau 5, and tau 7, respectively) was used to detect tau aggregates. 
In this assay, aza-9 significantly reduced the amount of tau aggregation detected (Figure 6.2 A). 
Further, the resulting tau aggregates from the inhibition reaction were visualized by electron 
microscopy- there were long filaments in the absence of aza-9. Upon treatment with aza-9, there 
were no filaments seen on the grid. There were small aggregates seen on the grids instead. Our 
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observations from the electron microscopy correlate well with the results obtained from the filter 



















Figure 6.2.  
A) Filter trap assay  
Assembly inhibition
























B) Electron microscopy images  
 
Figure 6.2. Inhibition of filament assembly at 200µM aza-9. 1-391 polymerization reactions 
were performed with 2 μM tau and 75 μM arachidonic acid either with or without 200 μM aza-9. 
The resulting amount of tau filament formation was determined using a filter trap assay (A). The 
amount of tau on the filter was detected using a mixture of antibodies tau 5, tau 7, and tau 12. (B) 
Aliquots of the reactions were prepared for negative stain electron microscopy. Representative 







6.3.2 Aza-9 completely disassembled pre-formed 1-391 filaments 
To determine whether aza-9 can disassemble preformed 1-391 aggregates, tau aggregation was 
allowed to proceed for 6 h before the addition of aza-9 to a final concentration of 200 μM. After 
12 h, the effect of aza-9 on the 1-391 aggregation was examined by a filter trap assay using the 
mixture of antibodies against normal tau (Figure 6.3 A). Aza-9 reduced the amount of preformed 
tau filaments. Electron microscopy was used to validate and extend the results from the filter trap 
assay. Aza-9 substantially reduced the pre-existing filament mass (Figure 6.3 B). 
6.3.3. Aza-9 disassembled 1-391 filaments in a dose-dependent fashion.  
The IC50 of aza-9 was determined using the filter trap assay. The amount of preformed filaments 
remaining following treatment with compounds for 12 h was reduced in a concentration-
dependent manner (Figure 6.3). Aza-9 had an IC50 of 212.25 ± 105.65 μM. 
6.4 Discussion  
Tau is altered in the diseased condition by post translational modifications such as 
hyperphosphorylation, acetylation, oxidation, ubiquitination and truncation. The modified tau 
further leads to formation of tau aggregates. Tau aggregates are composed of 3-repeat as well as 
4-repeat tau isoforms. It is therefore necessary to find tau aggregation inhibitors which are 
effective against all the different tau isoforms and on disease modified tau molecules. We 
identified azaphilones as a novel class of tau aggregation inhibitors which also have the ability to 
disassemble pre-formed tau filaments. In our study, we tested the effectiveness of azaphilones 
against full length tau. We therefore sought to determine whether the compounds are effective 
against aggregation enhancing tau mutants as well.  
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Figure 6.3.  
A)  Filter trap assay  
Disassembly



























B) Electron microscopy images  
 
Figure 6.2. Disassembly at 200µM aza-9. 1-391 polymerization reactions were performed with 
2 μM tau and 75 μM arachidonic acid either with or without 200 μM aza-9. The resulting amount 
of tau filament was determined using a filter trap assay (A). Negative values indicate that there 
was less detectable tau on the filter after treatment with a compound than was observed with 
monomeric tau in the absence of arachidonic acid. The amount of tau on the filter was detected 
using a mixture of antibodies tau 5, tau 7, and tau 12. (B) Aliquots of the reactions were prepared 
for negative stain electron microscopy. Representative images are shown for no compound 






Figure 6.3.  
 
 
Figure 6.3. IC50 determination tau filament disassembly. Polymerization reactions at 2 μM 
tau and 75 μM arachidonic acid were performed at room temperature. After 6 h, compounds 
were added to these reactions at several different concentrations, and the mixtures were 
incubated for an additional 12 h. The resulting amount of tau filaments in the reaction was 
determined by a filter trap assay detected by a mixture of antibodies to normal tau (tau 5, tau 7, 
and tau 12). The amount of polymerization was normalized to controls in the absence of 
compound (100%). The normalized data was plotted against the log of the inhibition 








At a concentration of 200 µM, aza-9 inhibited filament formation by 1-391 and also 
disassembled pre-formed 1-391 tau aggregates. The results observed in the filter trap assays 
correlated well with those of the transmission electron microscopy. Aza-9 therefore is effective 
against tau aggregation enhancing truncation mutant 1-391. We further obtained an IC50 value of 
212 µM for disassembly of 1-391 aggregates. This value is higher than the IC50 value obtained 
for disassembly of full length wild type tau by aza-9 and the experiments were done under 
similar experimental conditions. The aggregation rate of 1-391 truncation is higher than WT tau 
and therefore the aggregates could be differently packed or more compactly arranged than the 
WT tau aggregates. This may be one reason for the higher IC50 values.  
It would be interesting to test the effectiveness of aza-9 against other tau modifications such as 
hyperphosphorylated tau, FTDP-17 mutants and also on other isoforms of tau. This would 
provide us more knowledge about the mode of action of the compound. From a therapeutic point 
of view, tau aggregates found in patients suffering from AD and other tauopathies and will be 
composed of different variations of tau and a tau aggregation inhibitor would be useful only if it 








Chapter VII Conclusions and Future Directions 
 
7.1 Introduction 
Alzheimer’s disease (AD) is the most common form of dementia and it mainly causes problems 
with thinking, memory and behavior249.  The symptoms for AD develop slowly; patients develop 
cognitive dysfunction, the condition gets worse over time and eventually reaches a point when 
the symptoms are severe enough to interfere with everyday tasks such as moving, speaking, 
swallowing and breathing. The incidence of AD is currently on the rise due to lengthening life 
spans and changing lifestyles. The currently available knowledge in the field supports the idea 
that accumulation of misfolded or mutant proteins inside and/or outside neurons plays a major 
role in development of AD and other neurodegenerative disorders including tauopathies and 
Parkinson’s disease 250, 251. Misfolding and aggregation of proteins are thought to cause synaptic 
loss and neuronal death.  Tauopathies are a group of neurological disorders that are characterized 
by prominent intracellular aggregates composed of the microtubule-associated protein tau as a 
common mechanism for disease pathogenesis. Tau protein undergoes post-translational 
modifications that are believed to alter the protein structure and conformations such it is more 
prone to aggregate. The reasons for, and the process of, tau aggregation are not completely 
understood. Inhibiting tau aggregation is a potentially good target for therapeutics towards these 
diseases. Currently a tau aggregation inhibitor, a stable, reduced form of methylthioninium 
chloride, has reached Phase III clinical trials. But there remains a need to identify more 





7.2 Tau truncations  
Truncations are known to occur in tauopathies. Prior studies have shown that they can influence 
tau aggregation and are known to cause conformational changes that induce a misfolding cascade 
in Alzheimer’s disease (AD) and other tauopathies. Although the N and C terminal regions of tau 
protein play different roles in the process of tau aggregation, both termini are involved in 
generating pathological conformations of tau in the diseased state. They maintain the global 
hairpin conformation of tau and also make conformations identified by alz50 and tau66 
antibodies which identify tau in diseased form.  It is known that removal of the amino-terminal 
greatly inhibits the polymerization process by reducing the rate and extent of tau aggregation. 
The C-terminus on the other hand inhibits tau filament formation. Therefore, removal of the C-
terminal greatly enhances the polymerization process. We hypothesized that the site of truncation 
on the N –terminal and C-terminal will alter the structure of tau, thereby changing its global 
conformation and tendency for aggregation. Our studies described in chapter II, show that there 
are differences in the effects of N-terminal and C-terminal truncations on tau aggregation 
depending on the site of truncation. Upon using ARA as an inducer for tau aggregation, 
formation of either the Alz 50 or Tau 66 conformation may be required for tau filament 
assembly. This needs to be verified in the future using alz50 and tau 66 antibodies against all the 
truncation mutant aggregates. It would be interesting to test whether this holds true for heparin 
induced tau aggregation. Truncations at the N –terminal did not increase the total amount of tau 
aggregation compared to that of WT tau. But, there was an increase in the rate of tau aggregation 
upon elimination of the N –terminal amino acids required for Alz 50 conformation (a.a. 2-18). 
Upon further eliminating the proline rich region in tau (a.a 197-244) , the tau 66 conformation 
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cannot be formed and there was no tau filament formation observed under electron microscopy. 
We therefore believe truncation after alz50 N –terminal epitope and before the proline rich 
region, alters the tau structure such that it favors tau 66 conformation and therefore leads to 
increase in the rate of tau aggregation. The C-terminal truncations lead to an increase in tau 
aggregation. Truncation at N and C-terminal in 4-repeat isoforms further leads to inhibition of 
tau’s ability to aggregate, unlike that of the K19 construct (explained in chapter II discussion in 
detail). This may be because the intramolecular cross-linking of 4R-tau into compact monomers 
inhibits aggregation. Further studies are required to identify critical truncation sites on the N and 
C- termini which alter tau aggregation and function. Based on our results, we may infer that N-
terminal truncation events are unlikely to trigger tau aggregation process and may be playing a 
role in the disease progression after formation of NFTs. These results need to be tested under 
different experimental conditions – using different tau inducer molecules, truncations in different 
isoforms of tau and eventually test the effect of the truncation mutants on tau aggregation in cell 
culture and animal models.  
In my dissertation specifically, the study also contributed to finding aggregation enhancing tau 
truncations made under similar experimental conditions as WT tau (ARA induced reactions) to 
be tested against the tau aggregation inhibitor molecules. This is because it is important that tau 
aggregation inhibitors should be effective against disease modified tau aggregates. We chose 1-
391 truncation mutant for this study because in our experiments it increased the rate of tau 
aggregation and also the total amount of tau aggregation compared to WT tau. Aza-9 was seen to 




7.3 Azaphilones obtained from Aspergillus nidulans as tau aggregation inhibitors 
Tau aggregation is a common underlying molecular mechanism in pathogenesis of AD and other 
tauopathies. Inhibiting tau aggregation is therefore a potentially good therapeutic strategy for 
treating AD because it might help stop or reverse the disease progression. Fungi have been a 
great source of biologically important compounds. Dr. Berl Oakley’s lab was the first to identify 
and elucidate an azaphilone biosynthesis pathway. The azaphilones have a wide array of 
activities and therefore it may not be surprising that we are saw useful activities among the 
compounds we tested. One possible reason that fungi secrete anti-aggregation compounds may 
be due to the amyloid nature of bacterial biofilms252. We have identified compounds obtained 
from Aspergillus nidulans that have the ability to inhibit tau aggregation. The compounds have 
IC50 values in the micro molar range. We have identified a novel inhibitors, belonging to the 
azaphilone class of compounds, that inhibit tau aggregation and disassemble pre-formed tau 
filaments. We carried out structure activity relationship studies and have identified important 
sites on the compound that affect the ability of the compound to dissolve pre-formed tau 
aggregates (Figure 7.1). Aza-9 was the most potent compound with an IC50 value of 56μM for 
disassembly. Aza-9 had an acetate group at R2 and a Br at R1. This specific arrangement of 
groups seems to be important for compound activity. The presence of Br seemed more potent 
that the presence of Cl. Therefore, increased electronegativity at R2 position seems to have an 
impact on the ability of the compounds to disassemble tau aggregates. Azaphilones can react 
with primary amines to form vinylogous γ-pyridines. We therefore hypothesized that aza-9 could 
covalently bind to the primary amine of lysine in the hexapeptide motifs (VQIVYK), and that 
way would break the tau aggregates apart.  It would be possible to identify the covalent bond 
formation if any using mass spectrometry analysis and also we could identify the exact lysine 
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that could be being modified. Azaphilones provide a novel scaffold for tau aggregation inhibitors 
with great potential to create a variety of analogues, which could have better activity compared 
to the compounds we have identified currently.  
Based on preliminary data from NMR experiments we have identified the potential residues that 
interact with aza-9. The residues in and around the hexapeptide motif region of tau seem to be 
affected in a dose-dependent fashion. The NMR peak shifts suggested that the interaction 
between the compound and tau is in the micromolar range as were our IC50 values. Aza-9 was 
also potent against filaments formed from the aggregation-enhancing C-truncation mutant 1-391. 
It inhibited assembly of 1-391 filaments and also disassembled pre-formed 1-391 tau aggregates. 
This further adds potential value to the compound’s ability to inhibit aggregation. The azaphilone 
structural backbone is therefore a very promising new scaffold for effective tau aggregation 
inhibitors. 
7.4 Future directions    
In our work using tau truncation mutants, we developed insight into the effects of truncations on 
tau aggregation and function. It would be interesting to make other truncations apart from the 
ones used in our study to further narrow down the sites that are critical for polymerization. For 
example, 14-441 and 43-441 do not affect tau aggregation, whereas, 81-441 reduces the overall 
amount of tau aggregation. Truncations 201-441 and 256-441 completely inhibit formation of tau 
filaments. Therefore, it would be interesting to make truncations on sites between a.a. 43 and 81 
and sites before a.a. 201. Further, we could use conformation specific antibodies to determine 
whether the truncated tau can form the alz50 or tau 66 conformations. This will provide us more 




Figure 7.1  
 
Figure 7.1 Structure-activity relationship (SAR) studies. The potential sites which could or 










In the case of truncation mutants 201-441, 256-441 and 256-391, in the electron microscope 
images there are no tau filaments observed but we see tiny amorphous aggregates on the grids. 
We do not know whether these aggregates are toxic in nature. The truncation mutants 1-391, 81-
441 and 1-421 led to formation of tau filaments with smaller filament lengths and also increased 
number of oligomeric tau aggregates on the grids. We could use TOC1 and TNT1 antibodies to 
determine whether the tau aggregates formed by the truncation mutants are toxic in nature. In our 
study we have produced all the truncation mutants from the full-length tau protein. It would be 
interesting to study the effects of the same truncations in different isoforms of tau protein. The 
tau protein is present in all the six isoforms in the human brain and therefore it is important to 
see the effects of the truncation in every isoform to get a collective idea about their effects. 
Therefore, further characterization of the truncation mutants will likely help in explaining their 
role in aggregation. Eventually it would be useful to study their effects in vivo. This would help 
in understanding the role played by tau truncations in tauopathies and how these mechanisms are 
affecting the progression of sporadic tauopathies.  
We have identified a novel scaffold for tau aggregation inhibitors. The SAR studies give us 
several leads for the probable important chemical groups required in this scaffold structure for 
the anti-tau aggregation activity of the compounds (Figure 7.1). (The hydrophobic tail region of 
the scaffold hasn’t been explored in this study.) Therefore, in the future we could develop better 
analogues of the compounds that have increased activity and reduced effect on the tau-
microtubule interaction. Further studies on the interaction between the compounds and tau will 
help to determine the precise mechanism of action of these compounds. We could perform 
biochemical binding assays such as surface plasmon resonance to obtain a dissociation constant 
for the tau-compound interaction. Further studies with NMR such as peak assignment for full 
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length tau will help us in identifying the specific residues involved in the interaction. These 
compounds are in their initial stages of discovery and therefore it is not known whether they 
would be effective in vivo or whether they have the required pharmacokinetic properties and can 
cross the blood brain barrier. By knowing the mode of action of these compounds and the kind of 
interaction between the compound and tau, we would be able to better predict parameters 
important for drug development, which include the possible side effects of the drug, the mode of 
drug delivery, its chances of crossing the blood brain barrier and the drug dosage.  
Lastly, from a therapeutic point of view the tau aggregation inhibitors need to be effective 
against post translationally modified tau protein because the tau aggregates are known to be 
composed of hyper phosphorylated and truncated tau protein. Aza-9 inhibits aggregation 
enhancing 1-391 tau aggregates. We would like to test the effect of the compounds against 
FTDP-17 tau mutants, hyper phosphorylation mutants, as well as the truncation mutants. It 
would be interesting to see whether the treatment of the tau aggregates composed of post-
translationally modified tau would show a reduction in toxicity with the help of TOC1 and TNT1 
antibodies. These studies described here show that use of in vitro assays are useful in 
determining the effects of modifications of tau that could be altering key factors associated with 
tauopathies, and also for testing potential lead compounds for their ability to inhibit tau 
aggregation which can then be used to further analyze their effect in an in vivo setting.  It is a 
good system to compare and analyze results because it would be challenging and time 
consuming to directly compare results from animal models that utilize varying methods to induce 
tau aggregation. Through the continuation of these studies we can begin to gain a clearer 
understanding of the role of tau truncations in tau toxicity and progression of Alzheimer’s 
disease and other tauopathies.  Azaphilones are promising new class tau aggregation inhibitor 
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and further development of these compounds could hopefully help in advancing in the search for 
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